NZ622118B2 - Cardiovascular risk event prediction and uses thereof - Google Patents
Cardiovascular risk event prediction and uses thereof Download PDFInfo
- Publication number
- NZ622118B2 NZ622118B2 NZ622118A NZ62211812A NZ622118B2 NZ 622118 B2 NZ622118 B2 NZ 622118B2 NZ 622118 A NZ622118 A NZ 622118A NZ 62211812 A NZ62211812 A NZ 62211812A NZ 622118 B2 NZ622118 B2 NZ 622118B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- risk
- event
- biomarkers
- biomarker
- individual
- Prior art date
Links
- 230000000271 cardiovascular Effects 0.000 title claims abstract description 240
- 239000000090 biomarker Substances 0.000 claims abstract description 421
- 239000012472 biological sample Substances 0.000 claims abstract description 64
- 102100019493 CCL18 Human genes 0.000 claims abstract description 6
- 101700059693 CCL18 Proteins 0.000 claims abstract description 5
- 229920002395 Aptamer Polymers 0.000 claims description 68
- 239000003153 chemical reaction reagent Substances 0.000 claims description 52
- 230000000875 corresponding Effects 0.000 claims description 51
- 210000004369 Blood Anatomy 0.000 claims description 29
- 239000008280 blood Substances 0.000 claims description 29
- 108090001123 antibodies Proteins 0.000 claims description 26
- 102000004965 antibodies Human genes 0.000 claims description 26
- 210000002700 Urine Anatomy 0.000 claims description 22
- 108010048036 Angiopoietin-2 Proteins 0.000 claims description 20
- 208000010125 Myocardial Infarction Diseases 0.000 claims description 15
- 210000002966 Serum Anatomy 0.000 claims description 14
- -1 αantiplasmin Proteins 0.000 claims description 14
- 238000000099 in vitro assay Methods 0.000 claims description 8
- 229940035295 Ting Drugs 0.000 claims description 6
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 5
- 239000002853 nucleic acid probe Substances 0.000 claims description 5
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 1
- 102100003272 GDF11 Human genes 0.000 claims 1
- 101700065866 GDF11 Proteins 0.000 claims 1
- 102100004961 MMP12 Human genes 0.000 claims 1
- 108090000028 MMP12 Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 177
- 108090000623 proteins and genes Proteins 0.000 description 177
- 235000018102 proteins Nutrition 0.000 description 173
- 239000000523 sample Substances 0.000 description 105
- 201000010099 disease Diseases 0.000 description 73
- 238000004166 bioassay Methods 0.000 description 66
- 239000000203 mixture Substances 0.000 description 53
- 238000000034 method Methods 0.000 description 46
- 238000001514 detection method Methods 0.000 description 42
- 230000014509 gene expression Effects 0.000 description 41
- 150000007523 nucleic acids Chemical class 0.000 description 37
- 108020004707 nucleic acids Proteins 0.000 description 36
- 206010007559 Cardiac failure congestive Diseases 0.000 description 32
- 201000006233 congestive heart failure Diseases 0.000 description 32
- 239000007787 solid Substances 0.000 description 32
- 238000003384 imaging method Methods 0.000 description 29
- 230000027455 binding Effects 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 26
- 239000002609 media Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- 239000003550 marker Substances 0.000 description 23
- 238000005259 measurement Methods 0.000 description 23
- 230000001732 thrombotic Effects 0.000 description 23
- 229920001213 Polysorbate 20 Polymers 0.000 description 22
- 239000011324 bead Substances 0.000 description 22
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 22
- 102100000503 MATN2 Human genes 0.000 description 21
- 101700074505 MATN2 Proteins 0.000 description 21
- 150000002500 ions Chemical class 0.000 description 20
- 102100007747 ANGPT2 Human genes 0.000 description 19
- 210000001519 tissues Anatomy 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 17
- 208000008787 Cardiovascular Disease Diseases 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 16
- 230000004083 survival Effects 0.000 description 16
- 102100018427 GP6 Human genes 0.000 description 15
- 101700079100 GP6 Proteins 0.000 description 15
- 210000004027 cells Anatomy 0.000 description 15
- 238000004590 computer program Methods 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 230000001809 detectable Effects 0.000 description 13
- 108020004999 Messenger RNA Proteins 0.000 description 12
- 101700063429 NID1 Proteins 0.000 description 12
- 229920002106 messenger RNA Polymers 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 229920000272 Oligonucleotide Polymers 0.000 description 11
- 210000002381 Plasma Anatomy 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- 229920001239 microRNA Polymers 0.000 description 10
- 239000002679 microRNA Substances 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000006011 modification reaction Methods 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 230000001225 therapeutic Effects 0.000 description 10
- 102100016667 ESAM Human genes 0.000 description 9
- 101700066293 ESAM Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108020004388 MicroRNAs Proteins 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000004393 prognosis Methods 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000002596 correlated Effects 0.000 description 8
- 239000000975 dye Substances 0.000 description 8
- 230000002068 genetic Effects 0.000 description 8
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 210000001772 Blood Platelets Anatomy 0.000 description 7
- 210000002540 Macrophages Anatomy 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 239000012491 analyte Substances 0.000 description 7
- 238000002790 cross-validation Methods 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000003287 optical Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 102100014790 CHRDL1 Human genes 0.000 description 6
- 101710040404 CHRDL1 Proteins 0.000 description 6
- 206010044390 Transient ischaemic attack Diseases 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 239000002872 contrast media Substances 0.000 description 6
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 201000010875 transient cerebral ischemia Diseases 0.000 description 6
- 238000003828 vacuum filtration Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 229940088598 Enzyme Drugs 0.000 description 5
- 210000003734 Kidney Anatomy 0.000 description 5
- 210000000265 Leukocytes Anatomy 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000295 complement Effects 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 210000000056 organs Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000004450 types of analysis Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
- 230000035533 AUC Effects 0.000 description 4
- 101710026619 CLEC1A Proteins 0.000 description 4
- 102100013149 CLEC1A Human genes 0.000 description 4
- 210000004351 Coronary Vessels Anatomy 0.000 description 4
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 4
- 229940088597 Hormone Drugs 0.000 description 4
- 102100009235 IL18BP Human genes 0.000 description 4
- 101710007585 IL18BP Proteins 0.000 description 4
- 206010061255 Ischaemia Diseases 0.000 description 4
- 102100003515 LYZ Human genes 0.000 description 4
- 102100014892 MMP7 Human genes 0.000 description 4
- 101700057314 MMP7 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229920001850 Nucleic acid sequence Polymers 0.000 description 4
- 102000013566 Plasminogen Human genes 0.000 description 4
- 108010051456 Plasminogen Proteins 0.000 description 4
- 101710036428 ROR1 Proteins 0.000 description 4
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 4
- 102000024070 binding proteins Human genes 0.000 description 4
- 108091007650 binding proteins Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 238000003795 desorption Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000002255 enzymatic Effects 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000012216 imaging agent Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000250 revascularization Effects 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 200000000009 stenosis Diseases 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102100000322 ADIPOQ Human genes 0.000 description 3
- 102100018024 ANG Human genes 0.000 description 3
- 102100003297 CD5L Human genes 0.000 description 3
- 101700007422 CD5L Proteins 0.000 description 3
- 102100016705 COL18A1 Human genes 0.000 description 3
- 102100004730 CTSB Human genes 0.000 description 3
- 102100006332 CTSZ Human genes 0.000 description 3
- 102100014691 CXCL12 Human genes 0.000 description 3
- 101710043128 CXCL12 Proteins 0.000 description 3
- 239000003154 D dimer Substances 0.000 description 3
- 102100016628 EPHA1 Human genes 0.000 description 3
- 210000002744 Extracellular Matrix Anatomy 0.000 description 3
- 102100010042 GHR Human genes 0.000 description 3
- 102100018691 GRN Human genes 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000004851 Immunoglobulin G Human genes 0.000 description 3
- 108090001095 Immunoglobulin G Proteins 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 210000004185 Liver Anatomy 0.000 description 3
- 102100012750 MDK Human genes 0.000 description 3
- 210000001616 Monocytes Anatomy 0.000 description 3
- 101710034475 PAFAH1B1 Proteins 0.000 description 3
- 101710038787 PLA2G7 Proteins 0.000 description 3
- 102100004065 PLA2G7 Human genes 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 229960000856 Protein C Drugs 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102100000775 REN Human genes 0.000 description 3
- 102100003519 SELP Human genes 0.000 description 3
- 210000002536 Stromal Cells Anatomy 0.000 description 3
- 229940056501 Technetium 99m Drugs 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 3
- 238000001772 Wald test Methods 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 238000010968 computed tomography angiography Methods 0.000 description 3
- 230000002380 cytological Effects 0.000 description 3
- 238000007418 data mining Methods 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 108010052295 fibrin fragment D Proteins 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000024924 glomerular filtration Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000006148 magnetic separator Substances 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 108060005018 mobB Proteins 0.000 description 3
- 108010008217 nidogen Proteins 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 230000001575 pathological Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000000865 phosphorylative Effects 0.000 description 3
- 200000000002 platelet activation Diseases 0.000 description 3
- 229920003255 poly(phenylsilsesquioxane) Polymers 0.000 description 3
- 238000011176 pooling Methods 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 230000002285 radioactive Effects 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000000391 smoking Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- GKLVYJBZJHMRIY-OUBTZVSYSA-N technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-O 1H-indol-1-ium Chemical group C1=CC=C2[NH2+]C=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-O 0.000 description 2
- MGSKVZWGBWPBTF-UHFFFAOYSA-N AEBSF Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 2
- 108010031480 Artificial Receptors Proteins 0.000 description 2
- 102100014282 BMPER Human genes 0.000 description 2
- 101700066241 BMPER Proteins 0.000 description 2
- 102100017633 CAPG Human genes 0.000 description 2
- 101700031312 CAPG Proteins 0.000 description 2
- 102100013475 CCDC80 Human genes 0.000 description 2
- 108060001219 CCDC80 Proteins 0.000 description 2
- 102100012036 CCL23 Human genes 0.000 description 2
- 101700065817 CCL23 Proteins 0.000 description 2
- 102100013076 CD48 Human genes 0.000 description 2
- 101700012453 CD48 Proteins 0.000 description 2
- 102100010331 CHIT1 Human genes 0.000 description 2
- 101700035525 CNDP1 Proteins 0.000 description 2
- 102100007481 CNDP1 Human genes 0.000 description 2
- 102100007492 CNTFR Human genes 0.000 description 2
- 101700033928 CNTFR Proteins 0.000 description 2
- 102100005175 CSF1R Human genes 0.000 description 2
- 101700063802 CSF1R Proteins 0.000 description 2
- 101710006742 CST2 Proteins 0.000 description 2
- 102100014124 CST2 Human genes 0.000 description 2
- 102100002955 CST3 Human genes 0.000 description 2
- 101700064295 CTSB Proteins 0.000 description 2
- 102100015379 CTSS Human genes 0.000 description 2
- 101710041398 CTSZ Proteins 0.000 description 2
- 206010007554 Cardiac failure Diseases 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 2
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- 101710002199 DCTPP1 Proteins 0.000 description 2
- 102100008538 DCTPP1 Human genes 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 102100011170 EFNA5 Human genes 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- 210000002889 Endothelial Cells Anatomy 0.000 description 2
- 108010055211 EphA1 Receptor Proteins 0.000 description 2
- 102100015542 FCGR3B Human genes 0.000 description 2
- 101710044657 FCGR3B Proteins 0.000 description 2
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 2
- 101700003377 FUT5 Proteins 0.000 description 2
- 102100008582 FUT5 Human genes 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 229960004666 Glucagon Drugs 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101700007154 HPS4 Proteins 0.000 description 2
- 101710015954 HVA1 Proteins 0.000 description 2
- 206010019280 Heart failure Diseases 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102100015709 IGHG1 Human genes 0.000 description 2
- 101700070244 IGHG1 Proteins 0.000 description 2
- 102100015706 IGHG4 Human genes 0.000 description 2
- 101700023672 IGHG4 Proteins 0.000 description 2
- 102100004839 IL1R1 Human genes 0.000 description 2
- 101700060164 IL1R1 Proteins 0.000 description 2
- 102100008192 IL6ST Human genes 0.000 description 2
- 101710022768 IL6ST Proteins 0.000 description 2
- 101710006705 ITGA1 Proteins 0.000 description 2
- 102100019333 ITGA1 Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 2
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000019223 Interleukin-1 receptor family Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor family Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102100011339 KLK3 Human genes 0.000 description 2
- 101700058542 KLK3 Proteins 0.000 description 2
- 101700062538 KLKB1 Proteins 0.000 description 2
- 102100020314 LCN2 Human genes 0.000 description 2
- 101700065814 LEA2 Proteins 0.000 description 2
- 101700021338 LEC Proteins 0.000 description 2
- 101700077545 LECC Proteins 0.000 description 2
- 101700028499 LECG Proteins 0.000 description 2
- 101700063913 LECT Proteins 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 102000002561 MAP Kinase Kinase 2 Human genes 0.000 description 2
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 2
- 102100019096 MB Human genes 0.000 description 2
- 102100018200 MMP1 Human genes 0.000 description 2
- 102100004965 MMP14 Human genes 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- AAFYOVPTFNNVDN-UHFFFAOYSA-N N-methyl-N-phenacylnitrous amide Chemical compound O=NN(C)CC(=O)C1=CC=CC=C1 AAFYOVPTFNNVDN-UHFFFAOYSA-N 0.000 description 2
- 108060007121 NAGK Proteins 0.000 description 2
- 102100018731 NAGK Human genes 0.000 description 2
- 101710032690 NCAPG Proteins 0.000 description 2
- 102100000987 NID1 Human genes 0.000 description 2
- 101710034340 Os04g0173800 Proteins 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 102100001504 PLA2G2A Human genes 0.000 description 2
- 101710031207 PLA2G2A Proteins 0.000 description 2
- 206010049025 Persistent generalised lymphadenopathy Diseases 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N Pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 102100007239 RARRES2 Human genes 0.000 description 2
- 101710037409 RARRES2 Proteins 0.000 description 2
- 102100017729 ROR1 Human genes 0.000 description 2
- 101700058902 RORA Proteins 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 101700009186 SELP Proteins 0.000 description 2
- 102100003803 SERPINA4 Human genes 0.000 description 2
- 102100004479 SIGLEC7 Human genes 0.000 description 2
- 101710045220 SIGLEC7 Proteins 0.000 description 2
- 102100016121 SLPI Human genes 0.000 description 2
- 101700035022 SLPI Proteins 0.000 description 2
- 101710026488 SOD2 Proteins 0.000 description 2
- 101700033054 STC1 Proteins 0.000 description 2
- 102100002980 STC1 Human genes 0.000 description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 2
- 102400000612 Soluble CD163 Human genes 0.000 description 2
- 102100011240 THBS2 Human genes 0.000 description 2
- 102100009534 TNF Human genes 0.000 description 2
- 101710038526 TNFRSF1A Proteins 0.000 description 2
- 102100003095 TNFRSF1A Human genes 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 2
- 230000036462 Unbound Effects 0.000 description 2
- 102100019577 VCAM1 Human genes 0.000 description 2
- 101700058634 VCAM1 Proteins 0.000 description 2
- 102100015249 VEGFA Human genes 0.000 description 2
- 102100018715 YWHAG Human genes 0.000 description 2
- 101710010285 YWHAG Proteins 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 108060000096 argB Proteins 0.000 description 2
- 238000001854 atmospheric pressure photoionisation mass spectrometry Methods 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 230000001186 cumulative Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000003511 endothelial Effects 0.000 description 2
- 230000012953 feeding on blood of other organism Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 230000003899 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002608 insulinlike Effects 0.000 description 2
- 108010070145 interleukin-18 binding protein Proteins 0.000 description 2
- ZCYVEMRRCGMTRW-AHCXROLUSA-N iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 2
- 238000005040 ion trap Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010050180 kallistatin Proteins 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 238000000370 laser capture micro-dissection Methods 0.000 description 2
- 238000001001 laser micro-dissection Methods 0.000 description 2
- 101700036391 lecA Proteins 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 101700001016 mbhA Proteins 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000000116 mitigating Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000007837 multiplex assay Methods 0.000 description 2
- 230000002107 myocardial Effects 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 238000000575 proteomic Methods 0.000 description 2
- 238000010384 proximity ligation assay Methods 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 235000021003 saturated fats Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 101700044383 ssi Proteins 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 108010051423 streptavidin-agarose Proteins 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000000153 supplemental Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-BJUDXGSMSA-N (11)6C Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- YCKRFDGAMUMZLT-BJUDXGSMSA-N (18)F Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 1
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- CBXRMKZFYQISIV-UHFFFAOYSA-N 1-N,1-N,1-N',1-N',2-N,2-N,2-N',2-N'-octamethylethene-1,1,2,2-tetramine Chemical group CN(C)C(N(C)C)=C(N(C)C)N(C)C CBXRMKZFYQISIV-UHFFFAOYSA-N 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N 2,2'-bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- PJASADWILQWOAP-UHFFFAOYSA-N 2-(3-bromoazetidin-1-yl)acetonitrile Chemical compound BrC1CN(CC#N)C1 PJASADWILQWOAP-UHFFFAOYSA-N 0.000 description 1
- VHOQXEIFYTTXJU-UHFFFAOYSA-N 2-methylbuta-1,3-diene;2-methylprop-1-ene Chemical compound CC(C)=C.CC(=C)C=C VHOQXEIFYTTXJU-UHFFFAOYSA-N 0.000 description 1
- 101710003225 ADIPOQ Proteins 0.000 description 1
- 102100014482 AKR1A1 Human genes 0.000 description 1
- 101710038138 AKR1A1 Proteins 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102100001085 APOB Human genes 0.000 description 1
- 101700065507 APOB Proteins 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 210000004381 Amniotic Fluid Anatomy 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 210000003423 Ankle Anatomy 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101710013859 At1g04680 Proteins 0.000 description 1
- 108090000206 Autoantibodies Proteins 0.000 description 1
- 102000003852 Autoantibodies Human genes 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 229920000195 Bacterial small RNA Polymers 0.000 description 1
- 102000004954 Biglycan Human genes 0.000 description 1
- 108090001138 Biglycan Proteins 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100004144 C9 Human genes 0.000 description 1
- 101700052995 CASK Proteins 0.000 description 1
- 102100017642 CD84 Human genes 0.000 description 1
- 101710028436 CD84 Proteins 0.000 description 1
- 101700007670 CHIT1 Proteins 0.000 description 1
- 102100011734 CHST15 Human genes 0.000 description 1
- 101710023916 CHST15 Proteins 0.000 description 1
- 101710029642 COL18A1 Proteins 0.000 description 1
- 102100005176 CSF1 Human genes 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 108090000613 Cathepsin S Proteins 0.000 description 1
- 108010061117 Cathepsin Z Proteins 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 108010082155 Chemokine CCL18 Proteins 0.000 description 1
- 206010008479 Chest pain Diseases 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 108010027644 Complement C9 Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229960003624 Creatine Drugs 0.000 description 1
- 229940109239 Creatinine Drugs 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 description 1
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000007698 EC 1.1.1.1 Human genes 0.000 description 1
- 108010021809 EC 1.1.1.1 Proteins 0.000 description 1
- 102000013460 EC 1.1.1.37 Human genes 0.000 description 1
- 108010026217 EC 1.1.1.37 Proteins 0.000 description 1
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
- 108010015133 EC 1.1.3.9 Proteins 0.000 description 1
- 108010093894 EC 1.17.3.2 Proteins 0.000 description 1
- 102100010782 EGFR Human genes 0.000 description 1
- 229940022766 EGTA Drugs 0.000 description 1
- 101700033640 EPHA1 Proteins 0.000 description 1
- 102100011056 ERP29 Human genes 0.000 description 1
- 101700084413 ERP29 Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 1
- 108010043939 Ephrin-A5 Proteins 0.000 description 1
- 229940109526 Ery Drugs 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 102100011228 F10 Human genes 0.000 description 1
- 102100012318 F3 Human genes 0.000 description 1
- 240000003139 Ferula foetida Species 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N Gadolinium Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 102000002794 Glucosephosphate Dehydrogenase Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100016993 HNF1B Human genes 0.000 description 1
- 101700080837 HNF1B Proteins 0.000 description 1
- 240000008528 Hevea brasiliensis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 description 1
- 102100014231 IGF1 Human genes 0.000 description 1
- 101700074337 IGF1 Proteins 0.000 description 1
- 101710031099 IGFBP3 Proteins 0.000 description 1
- 102100014738 IGFBP3 Human genes 0.000 description 1
- 102100014735 IGFBP4 Human genes 0.000 description 1
- 101710031097 IGFBP4 Proteins 0.000 description 1
- 102100017933 IGFBP6 Human genes 0.000 description 1
- 101710031085 IGFBP6 Proteins 0.000 description 1
- 102100015708 IGHG2 Human genes 0.000 description 1
- 101700066107 IGHG2 Proteins 0.000 description 1
- 102100015707 IGHG3 Human genes 0.000 description 1
- 101700022634 IGHG3 Proteins 0.000 description 1
- 101700036616 IL16 Proteins 0.000 description 1
- 102100015977 IL16 Human genes 0.000 description 1
- 102100014181 IL1RL1 Human genes 0.000 description 1
- 102100008185 IL6R Human genes 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 101710006661 ITGB1 Proteins 0.000 description 1
- 102100001478 ITGB1 Human genes 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 229940027941 Immunoglobulin G Drugs 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010066572 Interleukin-1 Receptor-Like 1 Protein Proteins 0.000 description 1
- 102400000531 Interleukin-16 Human genes 0.000 description 1
- 108010065843 Interleukin-16 Proteins 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 229940057428 LACTOPEROXIDASE Drugs 0.000 description 1
- 101700078532 LCN2 Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000028880 Lactoperoxidase Human genes 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N Lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 102100008175 MGAM Human genes 0.000 description 1
- 101700019781 MMP1 Proteins 0.000 description 1
- 101700056196 MMP14 Proteins 0.000 description 1
- 101700037952 MRC2 Proteins 0.000 description 1
- 102100004734 MRC2 Human genes 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000016453 Macrophage-capping protein Human genes 0.000 description 1
- 108050006096 Macrophage-capping protein Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 229950006780 N-Acetylglucosamine Drugs 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 210000002445 Nipples Anatomy 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102100003129 OPCML Human genes 0.000 description 1
- 101710022656 OPCML Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 101700008436 PCSK1 Proteins 0.000 description 1
- 102100018945 PEBP1 Human genes 0.000 description 1
- 101700050015 PEBP1 Proteins 0.000 description 1
- 101700085733 PELA Proteins 0.000 description 1
- 101710007180 PGLYRP1 Proteins 0.000 description 1
- 102100004670 PGLYRP1 Human genes 0.000 description 1
- 102100001381 PLA2G1B Human genes 0.000 description 1
- 102100018916 PLAUR Human genes 0.000 description 1
- 101710008806 PLAUR Proteins 0.000 description 1
- 101700057431 PSMA2 Proteins 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 210000004910 Pleural fluid Anatomy 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010012809 Progranulins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 229940079877 Pyrogallol Drugs 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 101700026161 RIT2 Proteins 0.000 description 1
- 102100013037 RUNX2 Human genes 0.000 description 1
- 101700025421 RUNX2 Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- 230000036045 Renal clearance Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 102100004239 SOD2 Human genes 0.000 description 1
- 108010078070 Scavenger Receptors Proteins 0.000 description 1
- 102000014452 Scavenger Receptors Human genes 0.000 description 1
- 210000000582 Semen Anatomy 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101800000540 Soluble CD163 Proteins 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 210000003802 Sputum Anatomy 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 102000004896 Sulfotransferases Human genes 0.000 description 1
- 108090001033 Sulfotransferases Proteins 0.000 description 1
- 210000001179 Synovial Fluid Anatomy 0.000 description 1
- 101710041008 THBS2 Proteins 0.000 description 1
- 102100011904 TNFRSF10D Human genes 0.000 description 1
- 101710030968 TNFRSF10D Proteins 0.000 description 1
- 210000001138 Tears Anatomy 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N Tetrafluoroethylene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N Texas Red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229920003028 Threose nucleic acid Polymers 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 101700068732 VEGFA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000002268 Wool Anatomy 0.000 description 1
- 102100002634 XDH Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108091005736 adaptor proteins Proteins 0.000 description 1
- 102000035425 adaptor proteins Human genes 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000002686 anti-diuretic Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 239000003160 antidiuretic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 230000001174 ascending Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000003556 assay method Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 230000003143 atherosclerotic Effects 0.000 description 1
- 101700027839 bah Proteins 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001680 brushing Effects 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003392 chemiluminescence resonance energy transfer Methods 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical class CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 108010057052 chitotriosidase Proteins 0.000 description 1
- 235000020974 cholesterol intake Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001886 ciliary Effects 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940105756 coagulation factor X Drugs 0.000 description 1
- 108010048697 collagenase 1 Proteins 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000003636 conditioned culture media Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine zwitterion Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000001066 destructive Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 230000000378 dietary Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940012426 factor X Drugs 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 108091006088 gene-regulatory proteins Proteins 0.000 description 1
- 102000034448 gene-regulatory proteins Human genes 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 101710038860 hnf1ba Proteins 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 101700042928 lin-2 Proteins 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 108010053632 lipopolysaccharide-binding protein Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004880 lymph fluids Anatomy 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 230000001002 morphogenetic Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- QJGQUHMNIGDVPM-BJUDXGSMSA-N nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 238000003203 nucleic acid sequencing method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003364 opioid Effects 0.000 description 1
- 239000000382 optic material Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000000790 osteoblast Effects 0.000 description 1
- FXUHHSACBOWLSP-UHFFFAOYSA-N oxido(trioxo)technetium Chemical compound [O-][Tc](=O)(=O)=O FXUHHSACBOWLSP-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 1
- QVGXLLKOCUKJST-OUBTZVSYSA-N oxygen-17 Chemical compound [17O] QVGXLLKOCUKJST-OUBTZVSYSA-N 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 108010009051 peptidoglycan recognition protein Proteins 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000010452 phosphate Chemical group 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 102000005162 pleiotrophin Human genes 0.000 description 1
- 108010056011 pleiotrophin Proteins 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000000644 propagated Effects 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 150000003230 pyrimidines Chemical group 0.000 description 1
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010833 quantitative mass spectrometry Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 230000013878 renal filtration Effects 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000004805 robotic Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000004574 scanning tunneling microscopy Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 101710002420 sod Proteins 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 230000001502 supplementation Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 108010060887 thrombospondin 2 Proteins 0.000 description 1
- 108060008245 thrombospondin family Proteins 0.000 description 1
- 102000002938 thrombospondin family Human genes 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000001776 time-resolved fluorescence quenching Methods 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000000700 tracer Substances 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- VOBHRQFELWTZFS-AWLRYRRCSA-K trisodium;(4Z)-3-oxo-4-[(4-sulfonatonaphthalen-1-yl)hydrazinylidene]naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N/N=C3/C4=CC=C(C=C4C=C(C3=O)S(=O)(=O)[O-])S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 VOBHRQFELWTZFS-AWLRYRRCSA-K 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Abstract
method for determining the likelihood that an individual has increased risk of a Cardiovascular Event (CV) event comprises detecting, in a biological sample removed from an individual, biomarker values that each correspond to one of at least N biomarkers selected from Table 1 (defined in the specification), and determining the likelihood that the individual has increased risk for a CV event based on said biomarker values with N being 2 to 155 and one of the at least N biomarkers selected from Table 1 is CCL18. fication), and determining the likelihood that the individual has increased risk for a CV event based on said biomarker values with N being 2 to 155 and one of the at least N biomarkers selected from Table 1 is CCL18.
Description
Cardiovascular Risk Event tion and Uses Thereof
RELATEDNESS OF THE INVENTION
The subject application claims the t of priority from ding U.S.
Application No. 61/541,828, filed September 30, 201 1, which is incorporated herein in its
entirety.
FIELD OF THE INVENTION
The present application relates lly to the ion of biomarkers and a
method of evaluating the risk of a future cardiovascular event in an individual and, more
specifically, to one or more biomarkers, methods, devices, reagents, systems, and kits used to
assess an individual for the prediction of risk of developing a Cardiovascular (CV) Event over
a 5 year period. Such Events include but are not d to myocardial infarction, stroke,
congestive heart failure or death.
BACKGROUND
The following ption provides a summary of information relevant to the
t application and is not an admission that any of the information provided or publications
referenced herein is prior art to the present application.
Cardiovascular disease is the leading cause of death in the USA. There are a
number of existing and important predictors of risk of primary events (D'Agostino, R et al.,
"General vascular Risk Profile for Use in y Care: The Framingham Heart
Study" Circulation 117:743-53 (2008); and Ridker, P. et al., "Development and Validation of
Improved Algorithms fo rthe Assessment of Global Cardiovascular Risk in Women" JAMA
297(6):61 1-619 (2007)) and secondary events ak, M. et al. "Biomarkers to Predict
Recurrent Cardiovascular Disease: The Heart & Soul Study" Am. J . Med. 121:50-57 (2008))
which are widely used in clinical practice and therapeutic trials. Unfortunately, the
receiver-operating characteristic curves, hazard ratios, and concordance show that the
performance of existing risk factors and biomarkers is modest (AUCs of -0.75 mean that these
factors are only halfway between a coin-flip and perfection). In on to a need for improved
diagnostic performance, there is a need for a risk product which is both near-term and
personally responsive within individuals to cial (and destructive) interventions and
lifestyle changes. The commonly utilized Framingham equation has three main problems.
Firstly, it is too long term: it gives 10-year risk calculations but humans discount future risks
and are reluctant to make behavior and lifestyle modifications based on them. Secondly, it is
not very responsive to interventions: it's most heavily weighted factor is logical age,
which cannot decline. Thirdly, within the high risk population envisioned here, the
Framingham factors fail to discriminate well between high and low risk: the hazard ratio
between high and low quartiles is only 2.
Risk factors for cardiovascular disease are widely used to drive the intensity and
the nature of medical treatment, and their use has undoubtedly contributed to the reduction in
cardiovascular morbidity and mortality that has been ed over the past two s.
These factors have routinely been combined into algorithms but unfortunately they do not
capture all of the risk (the most common initial presentation for heart disease is still . In
fact they probably only capture half the risk. An area under the ROC curve of -0.76 is typical
for such risk s, and again, is only about halfway between a coin-flip at 0.5 and tion
at 1.0.
The addition of novel biomarkers to clinical risk scores has been disappointing.
For example, in the Framingham study (Wang et al., "Multiple Biomarkers for the tion
of First Major vascular Events and Death" N. Eng. J . Med. 355:2631-2637 (2006)) in
3209 people, the addition of 10 biomarkers (CRP, BNP, NT-proBNP, aldosterone, renin,
fribrinogen, D-dimer, plasminogen-activator inhibitor type 1, homocysteine and the urinary
albumin to creatinine ratio), did not icantly improve the AUC when added to existing risk
factors: the AUC for events 0-5 years was 0.76 with age, sex and conventional risk factors and
0.77 with the best combination of biomarkers added to the mix.
Early identification of patients with higher risk of a cardiovascular event within
a 1-10 year window is important because more aggressive treatment of individuals with
elevated risk may improve outcome. Thus, optimal ment requires agressive
intervention to reduce the risk of a cardiovascular event in those patients who are considered to
have a higher risk, while patients with a lower risk of a cardiovascular event can be spared
expensive and potentially invasive ents, which are likely to have no beneficial effect to
the t.
Biomarker selection for the prediction of risk of having specific disease state or
condition within a defined time period involves first the identification of markers that have a
measurable and statistically significant difference in populations in which the event has or has
not occurred during the time period for a specific medical ation. Biomarkers can include
secreted or shed molecules that parallel disease or condition development or progression and
readily diffuse into the blood stream from cardiovascular tissue or from surrounding tissues
and circulating cells in response to a cardiovascular event. The ker or set of kers
identified are generally ally validated or shown to be a reliable indicator for the original
intended use for which it was selected. Biomarkers can include small molecules, peptides,
proteins, and nucleic acids. Some of the key issues that affect the identification of biomarkers
include over-fitting of the available data and bias in the data.
A variety of methods have been utilized in an attempt to identify biomarkers
and diagnose or predict the risk of having disease or a condition. For protein-based markers,
these include two-dimensional electrophoresis, mass spectrometry, and immunoassay
methods. For nucleic acid markers, these include mRNA expression es, microRNA
profiles, FISH, serial is of gene expression (SAGE), large scale gene expression arrays,
gene sequencing and genotyping (SNP or small variant analysis).
The utility of mensional electrophoresis is limited by low detection
sensitivity; issues with protein solubility, charge, and hydrophobicity; gel reproducibility; and
the possibility of a single spot enting le proteins. For mass spectrometry,
depending on the format used, limitations revolve around the sample processing and
tion, sensitivity to low abundance proteins, signal to noise considerations, and inability
to immediately identify the detected protein. Limitations in immunoassay approaches to
biomarker discovery are centered on the inability of antibody-based multiplex assays to
measure a large number of analytes. One might simply print an array of high-quality antibodies
and, without sandwiches, measure the analytes bound to those antibodies. (This would be the
formal equivalent of using a whole genome of nucleic acid sequences to measure by
hybridization all DNA or RNA sequences in an organism or a cell. The hybridization
experiment works because hybridization can be a stringent test for identity. Even very good
antibodies are not stringent enough in selecting their binding partners to work in the context of
blood or even cell extracts because the protein ensemble in those matrices have ely
different abundances.) Thus, one must use a different ch with immunoassay-based
approaches to biomarker ery - one would need to use multiplexed ELISA assays (that is,
ches) to get ient stringency to measure many analytes aneously to decide
which analytes are indeed biomarkers. Sandwich immunoassays do not scale to high content,
and thus biomarker discovery using stringent ch immunoassays is not possible using
standard array formats. Lastly, dy reagents are subject to substantial lot variability and
reagent instability. The instant platform for protein biomarker discovery overcomes this
problem.
[001 1] Many of these s rely on or require some type of sample onation
prior to the analysis. Thus the sample preparation ed to run a sufficiently powered study
designed to identify and discover statistically relevant biomarkers in a series of well-defined
sample populations is ely difficult, costly, and time consuming. During fractionation, a
wide range of variability can be uced into the various samples. For example, a potential
marker could be le to the process, the concentration of the marker could be changed,
inappropriate aggregation or disaggregation could occur, and inadvertent sample
contamination could occur and thus e the subtle changes anticipated in early disease.
It is widely accepted that biomarker discovery and detection methods using
these technologies have serious limitations for the fication of diagnostic or predictive
biomarkers. These limitations include an inability to detect low-abundance biomarkers, an
inability to consistently cover the entire dynamic range of the proteome, irreproducibility in
sample processing and fractionation, and overall oducibility and lack of robustness of the
method. Further, these studies have introduced biases into the data and not adequately
addressed the complexity of the sample populations, including appropriate controls, in terms of
the distribution and randomization required to identify and validate biomarkers within a target
disease population.
Although efforts aimed at the discovery of new and effective biomarkers have
gone on for several decades, the efforts have been largely unsuccessful. Biomarkers for s
diseases typically have been identified in academic laboratories, usually through an accidental
discovery while doing basic research on some disease process. Based on the discovery and with
small amounts of clinical data, papers were published that suggested the identification of a new
ker. Most of these proposed biomarkers, however, have not been med as real or
useful biomarkers, primarily because the small number of clinical samples tested e only
weak statistical proof that an effective biomarker has in fact been found. That is, the initial
identification was not rigorous with respect to the basic elements of statistics. In each of the
years 1994 through 2003, a search of the scientific literature shows that thousands of references
ed to biomarkers were published. During that same time frame, however, the FDA
approved for diagnostic use, at most, three new protein biomarkers a year, and in several years
no new protein biomarkers were approved.
Based on the history of failed biomarker discovery efforts, theories have been
proposed that further promote the general understanding that biomarkers for diagnosis,
prognosis or prediction of risk of developing es and conditions are rare and difficult to
find. ker research based on 2D gels or mass spectrometry supports these notions. Very
few useful kers have been identified through these approaches. However, it is usually
overlooked that 2D gel and mass ometry measure proteins that are present in blood at
approximately 1 nM concentrations and higher, and that this ensemble of proteins may well be
the least likely to change with disease or the development of a particular condition. Other than
the instant biomarker discovery platform, proteomic biomarker discovery platforms that are
able to accurately measure protein expression levels at much lower concentrations do not exist.
[001 5] Much is known about biochemical pathways for complex human biology. Many
biochemical pathways culminate in or are d by secreted proteins that work locally within
the pathology; for example, growth factors are ed to stimulate the ation of other
cells in the pathology, and other factors are secreted to ward off the immune system, and so on.
While many of these secreted proteins work in a paracrine fashion, some operate distally in the
body. One d in the art with a basic understanding of biochemical pathways would
understand that many pathology-specific proteins ought to exist in blood at concentrations
below (even far below) the ion limits of 2D gels and mass spectrometry. What must
precede the identification of this relatively abundant number of disease biomarkers is a
mic platform that can analyze proteins at concentrations below those detectable by 2D
gels or mass spectrometry.
As is discussed above, cardiovascular events may be prevented by aggressive
ent if the propensity for such events can be accurately determined. Existing
multi-marker tests either require the collection of le samples from an individual or
require that a sample be partitioned between multiple assays. Optimally, an improved test
would require only a single blood, urine or other sample, and a single assay. Accordingly, a
need exists for biomarkers, methods, s, reagents, systems, and kits that enable the
prediction of Cardiovascular Events within a 5 year period.
Y OF THE INVENTION
The present application includes biomarkers, methods, reagents, devices,
systems, and kits for the prediction of risk of having a Cardiovascular (CV) Event within a 5
year period. The biomarkers of the present application were identified using a multiplex
SOMAmer-based assay which is described in detail in Examples 1 and 2 . By using the
r-based biomarker fication method described herein, this application describes
a surprisingly large number of CV event biomarkers that are useful for the prediction of CV
events. The sample population used to discover biomarkers associated with the risk of a CV
event was from the Heart & Soul Study, a prospective cohort study examining coronary artery
e progression in a population with pre-existing CV disease, including prior myocardial
infarction, evidence of greater than 50% stenosis in 1 or more coronary vessels,
exercise-induced ischemia by treadmill or nuclear testing or prior coronory revascularization.
The participants were ted from the San Francisco Bay Area. The CV event type and time
for the study population are shown in Table 4. In identifying these CV event kers, over
1000 proteins from over 900 individual samples were measured, some of which were at
concentrations in the low femtomolar range. This is about four orders of magnitude lower than
biomarker discovery experiments done with 2D gels and/or mass spectrometry.
While certain of the described CV event biomarkers are useful alone for
prediction of risk of having a CV event, methods are described herein for the grouping of
le subsets of the CV event biomarkers that are useful as a panel of biomarkers. Once an
individual biomarker or subset of biomarkers has been identified, the prediction of risk of a CV
event in an individual can be accomplished using any assay rm or format that is capable
of ing differences in the levels of the selected biomarker or biomarkers in a biological
sample.
r, it was only by using the SOMAmer-based biomarker fication
method described herein, wherein over 1000 separate potential biomarker values were
individually screened from a large number of individuals having previously been diagnosed
either as having or not having a CV event within a 5 year time frame, that it was possible to
identify the CV event biomarkers sed herein. This discovery approach is in stark contrast
to biomarker discovery from tissue samples, conditioned media or lysed cells as it queries a
more patient-relevant system that requires no translation to human pathology. Furthermore,
this form of blood-based measurement is far more applicable clinically.
Thus, in one aspect of the instant application, one or more biomarkers are
ed for use either alone or in various combinations to predict the risk of the occurrence of
a CV event within a 5 year time frame. Exemplary embodiments include the biomarkers
provided in Table 1, Col. 7, C_ NAME", which as noted above, were identified using a
multiplex SOMAmer-based assay, as described generally in Example 1 and more specifically
in Example 2. The markers provided in Table 1 are useful in the prediction of risk of having a
CV event within a 5 year time . The biomarkers from Table 2 and Table 3, respectively,
demonstrate the reduction of the 155 biomarkers from Table 1 to a smaller number which
performs the same task with less technical complexity and cost; however, other combinations
with r efficacy may be compiled from Table 1.
[002 1] While certain of the described CV event risk biomarkers are useful alone for the
prediction of risk of a CV event within 5 years, methods are also described herein for the
grouping of multiple subsets of the CV event risk biomarkers that are each useful as a panel of
two or more biomarkers. Thus, various embodiments of the instant application provide
combinations sing N biomarkers, wherein N is at least two biomarkers. In other
embodiments, N is selected to be any number from 2-155 biomarkers.
In yet other ments, N is selected to be any number from 2-7, 2-10, 2-15,
2-20, 2-25, 2-30, 2-35, 2-40, 2-45, 2-50, 2-55, or in successive increments of 5 for the upper
limit of the range, up to and ing 2-155. In other embodiments, N is selected to be any
number from 3-7, 3-10, 3-15, 3-20, 3-25, 3-30, 3-35, 3-40, 3-45, 3-50, 3-55, or in successive
increments of 5 for the upper limit of the range, up to and including 3-155. In other
embodiments, N is selected to be any number from 4-7, 4-10, 4-15, 4-20, 4-25, 4-30, 4-35,
4-40, 4-45, 4-50, 4-55, or in successive increments of 5 for the upper limit of the range, up to
and including 4-155. In other embodiments, N is selected to be any number from 5-7, 5-10,
-15, 5-20, 5-25, 5-30, 5-35, 5-40, 5-45, 5-50, 5-55, or in successive increments of 5 for the
upper limit of the range, up to and including 5-155. In other embodiments, N is ed to be
any number from 6-10, 6-15, 6-20, 6-25, 6-30, 6-35, 6-40, 6-45, 6-50, 6-55, or in successive
ents of 5 for the upper limit of the range, up to and including 6-155. In other
embodiments, N is selected to be any number from 7-10, 7-15, 7-20, 7-25, 7-30, 7-35, 7-40,
7-45, 7-50, 7-55, or in successive increments of 5 for the upper limit of the range, up to and
including 7-155. In other embodiments, N is selected to be any number from 8-10, 8-15, 8-20,
8-25, 8-30, 8-35, 8-40, 8-45, 8-50, 8-55, or in successive increments of 5 for the upper limit of
the range, up to and including 8-155. In other embodiments, N is selected to be any number
from 9-15, 9-20, 9-25, 9-30, 9-35, 9-40, 9-45, 9-50, 9-55, or in sive ents of 5 for
the upper limit of the range, up to and including 9-155. In other embodiments, N is selected to
be any number from 10-15, 10-20, 10-25, 10-30, 10-35, 10-40, 10-45, 10-50, 10-55, or in
successive ents of 5 for the upper limit of the range, up to and including 10-155. It will
be appreciated that N can be selected to encompass similar, but higher order, ranges.
As discussed above, cardiovascular events may be avoided by aggressive
ent if the propensity for such events can be accurately determined. Prior art
multi-marker tests either require the collection of multiple samples from an individual, or
require that a sample be partitioned between multiple assays. It would be preferred to provide
a prognostic assay that would require only a single biological sample, measured in a single
assay, rather than multiple s for different analyte types (lipids, proteins, metabolites) or
panels of es. The l benefit to a single sample test is simplicity at the point of use,
since a test with multiple sample collections is more complex to administer and this forms a
barrier to adoption. An additional advantage derives from g that single sample in a single
assay for le proteins. A single assay should mitigate unwanted ion due to
calibrating multiple assay results together. The test which forms the basis of this application is
such a "single sample, single assay" test. This combination of single sample and single assay
is a novel feature of this cardiovascular event risk test which addresses the logistic complexity
of collecting multiple samples and the problems and biohazards involved in splitting samples
into multiple aliquots for multiple independent analytical ures.
Cardiovascular disease is known to involve multiple ical processes and
tissues. Well known examples of biological systems and processes associated with
cardiovascular e are mation, thrombosis, disease-associated angiogenesis, platelet
activation, macrophage activation, liver acute response, extracellular matrix remodeling, and
renal function. These processes can be observed as a function of gender, menopausal status,
and age, and according to status of coagulation and vascular function. Since these systems
communicate partially through protein based signaling s, and multiple proteins may be
measured in a single blood sample, the invention provides a single , single assay
multiple protein based test focused on proteins from the specific biological systems and
processes involved in cardiovascular disease.
As is discussed herein, one of the central functions of measuring risk for a
vascular event is to enable the assessment of ss in se to treatment and
behavioral s such as diet and exercise. Current risk prediction methods such as the
Framingham equation, include clearly correlated clinical covariate information, the largest
such factor is the age of the subject. This makes the gham equation less useful for
monitoring the change in an individual's risk, although it may be accurate for a population. A
novel feature of this CV event risk test is that it does not require age as a part of the prognostic
model. The subject invention is based on the premise that, within the biology of aging, there
are causal factors which are variable and thus better used to assess risk. The invention is
ed on the belief that age itself is not a causal factor in the disease, and that age is acting
as a surrogate or proxy for the underlying biology. While age is indeed prognostic of CV
events, it cannot be used to assess individual improvement, and presumably the effect of age is
mediated through biological function. This effect can be better determined through
measurement of the relevant biology. In this invention, the proteins that are targeted are
involved in the biology of the disease. Thus, the invention captures the biological information
that is reflected in the correlation between age and risk of a CV event. In fact, adding a factor
for age to our model for risk based on proteins does not improve performance in ting
events.
The strategy to identify proteins from multiple processes ed in
cardiovascular disease itated choosing parameters that ed a wide range/diversity
of CV disease patients presenting with a variety of events or symptoms. Events due to
cardiovascular disease are heterogeneous, involving two main classes of event: otic and
CHF related events. Some presenting events may lack specific diagnostic information (e.g.,
death at home). In view of these characteristics of CV disease, the inventive test was
developed by measuring proteins involved from the biological processes associated with CV
disease, on blood samples from a broad range of events. This gy resulted in the inclusion
of information from multiple ses involved in the disease (e.g., angiogenesis, platelet
activation, macrophage activation, liver acute response, other lymphocyte inflammation,
extracellular matrix remodeling, and renal function). In order to develop a multiple protein
based prognostic single sample test for CV disease, the chosen study population was a high risk
group of subjects from the "Heart & Soul" study. By choosing this set of ts with a high
rate of CV events, it was le to determine risk associated with protein measurements more
accurately than would have been possible in the general population (within which events are
rarer). The development of the subject test on this high risk group, permitted identification of
protein biomarker combinations that could be generalized due to common biology. As a
result, the subject inventive test and biomarkers are likely to be effective beyond event
prediction in a larger population than those individuals matching the entry criteria of the "Heart
& Soul" study.
As is mentioned above, CV disease involves the blood coagulation system,
inflammatory white blood cells and platelet activation. The signals from the activation of these
systems in the body can be obscured due to common errors in sample preparation which lead to
platelets and white blood cells being only partially spun down from plasma samples. If these
cells are not completely spun down, they may be lysed by freeze-thaw when the s are
shipped and d. During the course of identification of the subject biomarkers, it became
apparent that in at least some cases, conventionally prepared samples contain whole cells and
ets after -thaw. During the subsequent proteomic assay, any whole cells would
lyse and interfere with the detection of proteins characteristic of the disease ses of in vivo
activation of platelets and monocytes. Thus, in one embodiment of the subject invention, an
additional step of re-spinning the samples after g is conducted prior to the assay. This
additional spin step can remove platelets and monocytes which would otherwise prevent the
identification of biomarkers related to platelet and monocyte activation. The additional step to
remove the insoluble and cellular ents of the samples (by spinning or filtering),
represents an advance for a cardiovascular event risk test which is believed to not be described
in the prior art.
While there are specific proteins from the literature which are known to be
prognostic for CV events such as apolipoprotein B, apolipoprotein A-l, BNP and CRP, and
which have known ations to CV disease, it has not been clear that a particular set of
protein measurements can be combined to m optimally in terms of prediction
performance due to common biological information being represented by multiple protein
measurements. A specific example of how combinations of proteins observed to vary during
CV disease may not provide an optimal tion performance, involves the many small
serum proteins excreted in urine which are related to renal function as measured by Glomerular
Filtration Rate (GFR). Poor renal function, as indicated by low GFR, is related to
cardiovascular risk. Thus, the many small ns associated with low GFR, appear to be
related to CV disease, but not independently. During the development of the t test,
corrections were made to protein measurements for estimated GFR in order to determine which
proteins provided additional prognostic value beyond GFR.
The measurement of GFR is clearly useful in predicting the risk of a CV event.
However, the clinical measurement of GFR involves urine tion over 24 hours, which
does not meet the subject rd of a "single sample, single assay" test. Other estimates of
GFR are less onerous; however, to meet the goal of a "single sample" prognostic test, the
strategy underlying the subject ion sought the use of the protein measurements
lves to provide GFR information for the risk analysis. For example, in the Table 3 ten
marker model, the protein ESAM strongly predicts CV event risk due to its correlation with
GFR. After correcting the measurements of the protein ESAM to remove the correlation with
estimated GFR, ESAM is no longer predictive of risk. This use of a protein such as ESAM to
convey the biological signal d to GFR in a "single sample, single assay" represents a
novel advance for the prognosis of a CV event.
The identification of the Table 3 biomarkers involved selection for proteins that
could work together in the prognosis of a CV event. Studies, such as Wang, T. et al., (2006)
N. Eng. J . Med. 355:2631-9, have shown that combinations of biomarkers often fail to provide
additional mance over simple risk ations using common clinical information such
as age and lipid levels. In order to avoid an ad hoc combination of biomarkers, the subject
ion provides a statistical analysis ure in which proteins were screened for both for
their individual prognostic power, and also, crucially, the capability of the proteins to work
together synergistically to e the prognostic value of the combination. Multiple
independent biological processes are represented in the Table 3 ten marker protein model
provided herein.
[003 1] In one embodiment, the invention comprises a method for evaluating the risk of
a future cardiovascular (CV) Event within a 5 year time period in a population. This method
comprises the detection, in a biological sample from an individual of the population, biomarker
values that each correspond to one of at least N biomarkers selected from Table 1, wherein the
risk for an individual of a CV event is ted, based on the biomarker values, and wherein N
= 2 - 155. In another embodiment, the biomarkers are selected from Table 2 and N=2-46. In
r embodiment, the biomarkers are selected from Table 3 and N=2-10.
In one embodiment, the selection of a population is such that the population is
terized as having no prior history of cardiovascular e. In the alternative, the
population may be selected such that it is characterized as having a prior history of
cardiovascular disease.
The prior history can comprise prior myocardial infarction, angiographic
ce of greater than 50% stenosis in 1 or more coronary vessles, exercise-induced
ischemia by ill or nuclear testing or prior coronary revascularization.
Further, the population may be selected such that it is characterized by genetic
risk factors comprising mutations, single nucleotide polymorphisms and insertion/deletions.
Such genetic risk factors can be used to complement the evaluation of risk .
The tion of risk of a CV event can be measured on a dynamic scale that is
responsive to change over time in response to interventions comprising eutics,
nutritional programs, supplementation, lifestyle modification, smoking cessation programs and
disease management protocols.
The foregoing methods ng to evaluation of CV event risk over a 5 year
period can be used to allocate the individuals into increased or decreased disease management
programs, based on their biomarker values. The method can also be used to stratify the
individuals into ent risk bands relating to life insurance coverage depending on said
biomarker value. Also, it can be used for evaluation of CV event risk in order to fy the
individuals into different risk bands relating to health insurance coverage ing on said
biomarker value. Additionally, it can be used to assess potential candidates for partnership
depending on biomarker values.
Further, the foregoing methods for CV event risk prediction can be used to:
predict medical resource consumption of the population based on the biomarker ; use the
biomarker value of the individual as an entry criterion for clinical trials of CV therapeutics;
prediction of efficacy of clinical trial results based on said ker value; use the biomarker
value for vascular safety llance of a CV therapeutic or any therapeutic agent; use
the biomarker value as a surrogate endpoint of efficacy of CV therapeutics; and/or r
compliance with any intervention, dietary or therapeutic protocol based on said biomarker
value. In regard to the CV safety surveillance of a CV therapeutic or any therapeutic agent,
such surveillance is important in large, costly, required phase 3 CV safety studies for CV
therapeutic and non-cardiovascular drugs for nearly every chronic use.
The t method for evaluating a CV event risk can also be used to select or
refer the individual for other diagnostic procedures based on said biomarker value.
Additionally, the subject method can be used to select a CV therapeutic based on biomarker
value.
In the subject method for evaluation of CV event risk, the biomarker values can
be ed by performing an in vitro assay. The in vitro assay can involve at least one capture
reagent corresponding to each of the biomarkers, and further can include at least one capture
reagent from the group ting of SOMAmers, antibodies, and a nucleic acid probe. In a
preferred embodiment, the capture reagent is a SOMAmer.
In another embodiment, the in vitro assay can be selected from the group
ting of an immunoassay, a SOMAmer-based assay, a histological or cytological assay,
and an mRNA expression level assay.
In the t methods, the biological sample can be whole blood, plasma,
serum, urine or the like. In a red embodiment, the biological sample is serum, plasma or
urine.
Additionally, it is provided that in the subject methods the individual can be a
mammal, and in particular, a human.
In alternative embodiments of the subject s, N = 3 - 10; N = 3 - 15; N =
2 - 10; N = 4 - 10; or N = 5 - 10.
In another embodiment, the invention provides for a computer-implemented
method for evaluating the risk of a cardiovascular (CV) Event. This method can include
retrieving on a computer biomarker information for an individual, wherein the biomarker
information comprises biomarker values that each correspond to one of at least N biomarkers
selected from Table 1; ming with the computer a classification of each of the biomarker
values; and indicating a result of the evaluation of risk for a CV event for said individual based
upon a plurality of classifications, and wherein N = 2 - 155. In alternate embodiments of this
method, the biomarkers can be selected from Table 2 (with N=2-46) or Table 3 (with N=2-10).
The result of the evaluation of risk of a CV event for the individual can be
displayed a computer display.
In another embodiment, the invention comprises a computer program product
for evaluating the risk of a CV event. The computer program product can include a computer
readable medium embodying program code executable by a processor of a computing device or
, where the program code comprises: code that retrieves data attributed to a ical
sample from an individual, wherein the data comprises ker values that each correspond
to one of at least N biomarkers selected from Table 1, where the biomarkers were detected in
the biological sample; and code that executes a classification method that indicates a result of
the evaluation of risk for a CV event of the dual as a function of said biomarker .
When the biomarkers are selected from Table 1, col. 7, N = 2 - 155. In other embodiments, the
biomarkers can be selected from Table 2 (with ) or from Table 3 (with N=2-10).
The classification method can use a continuous score or measure or risk metric.
The classification method can also use two or more classes.
The subject invention further comprises a method for screening an dual
for evaluation of risk of a CV event. This method comprises the detection, in a biological
sample from an individual, biomarker values that each correspond to one of at least N
biomarkers selected from Table 1, wherein the dual is evaluated for risk for a CV event
based on said biomarker values, and wherein N = 2 - 155. In other ments the
kers can be selected from Table 2 (with N=2-46) or from Table 3 (with ),
tively.
In the subject methods, the detection of the biomarker values can be done in an
in vitro assay. Such in vitro assay can include at least one capture reagent corresponding to
each of the biomarkers, and can further comprise the selection of the at least one capture
reagent from the group consisting of SOMAmers, antibodies, and a nucleic acid probe.
Preferably, the at least one capture reagent is a SOMAmer. The in vitro assay can be selected
from an immunoassay, a SOMAmer-based assay, a histological or cytological assay, and an
mRNA sion level assay.
The biological sample can be selected from whole blood, plasma, serum, urine
and the like. Preferably, the biological sample is serum, plasma or urine. In the subject
method, the individual can be a mammal, and is preferably a human.
In one of the embodiments of the subject invention, it is provided that the
individual is evaluated for risk of a CV event, based on said biomarker values and at least one
item of additional biomedical information corresponding to said individual. At least one item
of additional biomedical information can include, but is not limited to, any of the following:
(a) information corresponding to the presence of cardiovascular risk factors including one or
more of a prior myocardial infarction, angiographic evidence of greater than 50% stenosis in
one or more coronary vessels, se-induced ischemia by treadmill or r testing or
prior coronary revascularization; (b) information corresponding to physical descriptors of said
individual; (c) ation corresponding to a change in weight of said individual; (d)
information corresponding to the ethnicity of said dual; (e) information corresponding to
the gender of said individual; (f) information corresponding to said individual's smoking
y; (g) information corresponding to said individual's alcohol use history; (h) information
ponding to said individual's occupational history; (i) information corresponding to said
individual's family history of cardiovascular disease or other circulatory system conditions; j)
information corresponding to the presence or absence in said individual of at least one genetic
marker correlating with a higher risk of cardiovascular disease in said dual or a family
member of said individual; (k) information corresponding to clinical symptoms of the
individual; (1) information corresponding to other laboratory tests; (m) information
corresponding to gene expression values of the individual; (n) information corresponding to
said individual's ption of known cardiovascular risk factors such as diet high in
saturated fats, high salt; (o) information corresponding to the individual's g studies
including electrocardiogram, echocardiography, carotid ultrasound for intima-media thickness,
flow mediated dilation, pulse wave velocity, ankle-brachial index, stress echocardiography,
myocardial perfusion imaging, coronary calcium by CT, high tion CT angiography, MRI
imaging, and other imaging modalities; and (p) information about medications .
The ion further comprises a panel of kers for evaluating the risk of
a future CV event within a five year time period, wherein the panel ses N biomarkers
selected from the group consisting of the biomarkers of Table 1, wherein N = 2 - 155. In
alternative embodiments, the biomarkers are selected from Table 2, wherein N = 2 - 46 or from
Table 3, wherein N = 2 - 10.
In another aspect, the invention comprises a method for screening an individual
in a population by evaluating or prognosing the risk of a future CV event within a 5 year period,
by detecting, in a ical sample from the individual, a ker value for angiopoietin 2,
and ining the risk of a future CV event on the basis of the angiopoietin 2 biomarker
value. The biomarker value can be expressed as a measurement score or a classification into
one of a plurality of classifications.
In a variation of the screening method using angiopoietin 2, the subject
invention also comprises adding to the method, before the determining step, the step
comprising providing information regarding the individual's use of a statin. Thus, the
determining of the risk of a future CV event is on the basis of the angiopoietin 2 biomarker
value and the statin information.
The angiopoietin 2 is surprisingly useful in prognosing a secondary
cardiovascular event for individuals on statins. s have been reported in the prior art to
not only reduce the risk of a secondary cardiovascular event, but also cause an increase in
angiopoietin 2. This rise in angiopoietin 2 would have been expected to negate it's use as a
biomarker. Unexpectedly, angiopoietin 2 has trated that it is a good marker for
prediction of secondary cardiovascular events in high risk individuals.
The method of detecting angiopoietin 2 biomarker value can se the
further step of: detecting in the biological sample a biomarker value for one or more of
MMP7, CHRDL1, MATN2, PSA-ACT biomarkers or a combination thereof. The method
can additionally involve the detection, in the biological , of biomarker values that each
correspond to N biomarkers selected from the biomarkers of Table 3, n N = 2-10.
In another , the invention provides a panel of biomarkers for screening an
individual in a population by ting or prognosing the risk of a future CV event within a 5
year . The panel includes at least the angiopoietin 2 biomarker. This panel can further
include one or more of the MMP7, , MATN2, PSA-ACT biomarkers or any
combination thereof. In on, the panel can include one or more biomarkers selected from
Table 3, wherein N = 2-10.
In r embodiment, the invention provides a method for screening an
individual by evaluating the risk of a future CV event within a 5 year period, wherein the
evaluating comprises a differential prognosis of a otic event or congestive heart failure
(CHF) event. This method comprises: ing in a biological sample from the individual
of the population, biomarker values that each correspond to GPVI biomarker for prognosis of
the thrombotic event, and MATN2 biomarker for the prognosis of the CHF event. The
method can involve the r step of detecting in the biological sample biomarker values for
N biomarkers selected from the group of biomarkers set forth in Table 3, wherein N = 3-10.
The thrombotic event can include any of a myocardial infarction (MI), transient ischemic
attack (TIA), stroke, acute coronary syndrome and a need for coronary re-vascularization.
Further provided is a panel of biomarkers for screening an individual in a
population by evaluating or prognosing the risk of a future CV event within a 5 year period,
wherein the panel ses a GPVI biomarker and a MATN2 biomarker. The panel can
onally include at least one of N biomarkers selected from the group consisting of the
biomarkers set forth in Table 3.
Multiple classes of treatment for CV disease are available, reflecting the y
of biological systems involved. For example, anti-thrombotic, platelet inhibitor, lipid
metabolism, fluid and electrolyte balance tions, and beta blockers, have been used in the
treatment of CV disease. In order to guide treatment, it is useful to identify not only the
l risk, but also distinguish the class of event indicated by the biology. The foregoing
method using MATN2 and GPVI allows for guishing the probable event classes of
thrombotic events and CHF events. The GPVI is more specific to the development of the
thrombotic event, and the MATN2 is more specific to CHF events. The specifity of GPVI for
thrombotic events is demonstrated in Figures 8A and 8B. The specificity of MATN2 for
prognosis of CHF is illustrated in Figures 9A and 9B. These differences can be interpreted in
terms of the related biological processes. This multiple protein based test can therefore e
the patient with information to distinguish the risk of developing CHF versus the risk of
thrombotic events. This is a significant and ant feature of the invention that is believed
not to be described in the prior art.
In addition to providing prognosis of CV event risk based on protein
measurements alone, the subject method also provides the advantage of a more complete
e derived from taking into account simple information such as gender, medication, other
s such as LDL cholesterol, HDL cholesterol, total cholesterol, and other conditions such
as diabetes. Such models can be built upon the existing Table 3 ten protein model introduced
here.
Further provided herein is a kit for screening an individual in a population by
evaluating or prognosing the risk of a future CV event within a 5 year . The kit includes
the ing components: at least one of the biomarkers set forth in Table 1; at least one
ponding capture reagent, n each of the corresponding capture reagents is specific
to the selected biomarkers; and a signal generating material, said material being specific to the
selected corresponding biomarkers and/or corresponding capture reagents, wherein each signal
is activated upon binding of each capture reagent to the corresponding biomarker.
In another aspect, the kit of can comprise one or more biomarkers selected from
the group consisting of: angiopoietin 2 biomarker; angiopoietin 2 biomarker and any
ker selected from the group consisting of MMP7, CHRDL1, MATN2, PSA-ACT and
any combination thereof; a biomarker selected from the group consisting of GPVI biomarker,
MATN2 biomarker and any combination thereof; N biomarkers selected from the group of
biomarkers set forth in Table 3, wherein N = 2-10; and any combination thereof.
The capture reagents of the kits can be any one or more of SOMAmers,
antibodies, and nucleic acid probes or a combination thereof. The kit can also include
ctions or one or more software or computer program products for classifying the
individual from whom the biological sample was obtained, as either having or not having
increased risk of a CV event.
In another embodiment, the subject ion comprises a classifier comprising
the biomarkers of Table 1, col. 7, Table 2 or Table 3.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1A is a flowchart for an ary method for the prediction of a CV
event in a biological . Figure 1 B is a flowchart for an ary method for the
prediction of a CV event in a biological sample using a naive Bayes classification method.
Figure 2A shows a Principal component analysis for a subgroup of cases with
Events and controls with no CV events within 6 months. The cases with events are partially
separated from the controls along the vertical axis.
Figure 2B shows a DSGA analysis for a subgroup of cases with Events and
controls with no CV events within 6 . The cases with events are partially separated from
the controls along the horizontal axis.
Figure 3 provides a risk score analysis for the study population. This score was
calculated by building a simple Cox proportional hazard model using the thm of the
measurements of the ten proteins in Table 3. The population was split into quintiles based on
this score. The Kaplan Meier plots in Figure 3 demonstrate how these quintiles differ in the
proportion of the individual experiencing a cardiovascular event or death for various event
types.
Figure 3A shows the Kaplan Meier plots of all deaths and cardiovascular events
of the study population, with the tion split into quintiles based on the Table 3 n
scores.
Figure 3B shows the Kaplan Meier plots for the cases of CV events:
unclassified deaths, those deaths without a known proximal cause such as MI or CHF
(congestive heart failure), with the population split into quintiles based on the Table 3 protein
scores.
Figure 3C shows the Kaplan Meier plots for the cases of CV events: incident
CHF with the population split into quintiles based on the Table 3 protein scores.
Figure 3D shows the Kaplan Meier plots for the cases of CV : CHF
recurrence for chronic CHF patients (those with a previous diagnosis of CHF) with the
population split into quintiles based on the Table 3 protein scores.
Figure 3E shows the Kaplan Meier plots for the cases of CV events: thrombotic
event (MI + ) with the population split into quintiles based on the Table 3 protein scores.
Figure 3F shows the Kaplan Meier plots for the cases of CV events: all CHF,
with the tion split into quintiles based on the Table 3 protein scores.
Figure 4 illustrates an ary computer system for use with various
computer-implemented methods described herein.
Figure 5 is a art for a method of indicating evaluating risk of a CV event
in accordance with one embodiment.
Figure 6 is a flowchart for a method of evaluating risk of a CV event in
accordance with one embodiment.
Figure 7 illustrates an exemplary aptamer assay that can be used to detect one or
more CV event biomarkers in a biological sample.
Figure 8 shows the Kaplan Meier plots based on GPVI, one of the ten proteins
in Table 3, demonstrating that this protein guishes n thrombotic and CHF .
The population is split into quartiles of GPVI. Figure 8A shows the highest quartile of GPVI is
prognostic for otic cardiovascular events. Figure 8B shows that the quartiles of GPVI
have little or no discriminative ability to forecast CHF events.
Figure 9 shows the Kaplan Meier plots based on MATN2, one of the ten
proteins in Table 3, demonstrating that this protein distinguishes between thrombotic and CHF
events. The population is split into quartiles of MATN2. Figure 9A shows that the quartiles of
MATN2 are not prognostic for thrombotic cardiovascular events. Figure 9B shows that
individuals from the highest quartile of MATN2 have a higher rate of CHF events.
Figure 10 shows the Kaplan Meier plots of all 538 subjects taking statin
medication showing that those individuals in the 4th quartile of the population distribution for
angiopoietin-2 suffer cardiovascular events at an sed rate ed to those not in the
4th Quartile for angiopoietin-2. Thus despite the effects of treatment with statins,
angiopoietin-2 is a useful biomarker of the risk of CV events.
Figure 11 shows the Kaplan Meier plots of all 538 subjects taking statin
medication showing that CHRDLl is associated with the event free al of vascular
events in individuals treated with statin. Thus despite the effects of treatment with statins,
CHRDLl is a useful biomarker of the risk of CV events.
DETAILED DESCRIPTION
Reference will now be made in detail to representative embodiments of the
invention. While the invention will be described in conjunction with the enumerated
embodiments, it will be understood that the invention is not intended to be limited to those
embodiments. On the contrary, the invention is intended to cover all alternatives,
modifications, and equivalents that may be included within the scope of the present invention
as defined by the claims.
One d in the art will recognize many methods and materials similar or
equivalent to those described herein, which could be used in and are within the scope of the
practice of the t invention. The present invention is in no way d to the methods and
als described.
Unless defined ise, cal and scientific terms used herein have the
same meaning as commonly understood by one of ordinary skill in the art to which this
invention belongs. Although any methods, devices, and materials similar or equivalent to those
described herein can be used in the practice or testing of the invention, the preferred methods,
devices and als are now described.
All publications, published patent documents, and patent applications cited in
this application are indicative of the level of skill in the art(s) to which the application pertains.
All publications, published patent documents, and patent applications cited herein are hereby
incorporated by reference to the same extent as though each individual publication, published
patent document, or patent application was specifically and individually indicated as being
incorporated by reference.
As used in this application, ing the appended , the singular forms
"a," "an," and "the" include plural references, unless the content clearly dictates otherwise, and
are used interchangeably with "at least one" and "one or more." Thus, reference to "a
SOMAmer" es mixtures of SOMAmers, reference to "a probe" includes mixtures of
probes, and the like.
As used herein, the term "about" represents an ificant modification or
variation of the numerical value such that the basic function of the item to which the numerical
value relates is unchanged.
As used herein, the terms "comprises," "comprising," "includes," "including,"
"contains," ining," and any variations f, are intended to cover a non-exclusive
inclusion, such that a process, method, product-by-process, or composition of matter that
ses, es, or contains an element or list of elements does not include only those
elements but may include other elements not expressly listed or inherent to such process,
method, product-by-process, or composition of matter.
The present application includes biomarkers, methods, devices, reagents,
systems, and kits for the prediction of risk of CV events within a defined period of time, such as
years.
"Cardiovascular Event" means a failure or malfunction of any part of the
circulatory system. In one embodiment, "Cardiovascular Event" means stroke, transient
ischemic attack (TIA), myocardial infarction (MI), sudden death attributable to malfunction of
the circulatory system, and/or heart failure. In another embodiment, "Cardiovascular Event"
means any of the foregoing ctions and/or le angina, need for stent or angioplasty,
or the like.
Cardiovascular Events include "Congestive Heart Failure" or "CHF" and
"thrombotic events." Thrombotic Events include Mis, transient ischemic attacks (TIA),
stroke, acute coronary syndrome and need for ry re-vascularization.
In one aspect, one or more biomarkers are provided for use either alone or in
various combinations to evaluate the risk of a future CV event within a 5 year time period with
CV events defined as myocardial infarction, stroke, death and tive heart failure.
Thrombotic events (Figure 3e) consist of dial infarction and stroke combined. As
described in detail below, exemplary ments include the biomarkers provided in Table 1,
Col. 7, which were identified using a multiplex SOMAmer-based assay that is described
generally in Example 1 and more specifically in e 2.
Table 1, Col. 7, sets forth the findings obtained from analyzing hundreds of
individual blood s from patients who have had a CV event within a 6 month - 10 year
time frame (Event Positive) after l blood draw (time point 1), and hundreds of equivalent
individual blood samples from individuals who did not have a CV event within that time frame
(Event Negative). The potential biomarkers were ed in individual samples rather than
pooling the Event Positive and Event Negative blood samples; this allowed a better
understanding of the individual and group variations in the phenotypes associated with the
presence and absence of a CV event. Since over 1000 n ements were made on
each sample, and several hundred samples from each of the Event Positive and the Event
Negative populations were individually measured, the biomarkers reported in Table 1, Col. 7
resulted from an analysis of an uncommonly large set of data. The measurements were
analyzed using the methods bed in the section, "Classification of Biomarkers and
Calculation of Risk Scores" herein. Table 1, Col. 7 lists the 155 biomarkers found to be useful
in stratifying the population of individuals ing to their sity to exhibit a future CV
event in the period of 0-5 years after blood sample was drawn. The Kaplan-Meier curves in
Figures 3A-3F show a strong dependence of event risk upon quintile of a score determined by a
small subset of such biomarkers, as listed in Table 3.
While certain of the bed CV event kers are useful alone for
evaluating the risk of a CV event, methods are also described herein for the grouping of
multiple subsets of the CV event biomarkers, where each grouping or subset selection is useful
as a panel of three or more biomarkers, interchangeably referred to herein as a "biomarker
panel" and a panel. Thus, various embodiments of the instant ation provide combinations
comprising N biomarkers, wherein N is at least two biomarkers. In other embodiments, N is
selected from 2-155 biomarkers.
In yet other embodiments, N is selected to be any number from 2-7, 2-10, 2-15,
2-20, 2-25, 2-30, 2-35, 2-40, 2-45, 2-50, 2-55, or in successive ents of 5 for the upper
limit of the range, up to and including 2-155. In other embodiments, N is selected to be any
number from 3-7, 3-10, 3-15, 3-20, 3-25, 3-30, 3-35, 3-40, 3-45, 3-50, 3-55, or in successive
increments of 5 for the upper limit of the range, up to and ing 3-155. In other
embodiments, N is selected to be any number from 4-7, 4-10, 4-15, 4-20, 4-25, 4-30, 4-35,
4-40, 4-45, 4-50, 4-55, or in successive increments of 5 for the upper limit of the range, up to
and including 4-155. In other embodiments, N is selected to be any number from 5-7, 5-10,
-15, 5-20, 5-25, 5-30, 5-35, 5-40, 5-45, 5-50, 5-55, or in successive increments of 5 for the
upper limit of the range, up to and including 5-155. In other embodiments, N is selected to be
any number from 6-10, 6-15, 6-20, 6-25, 6-30, 6-35, 6-40, 6-45, 6-50, 6-55, or in successive
increments of 5 for the upper limit of the range, up to and including 6-155. In other
embodiments, N is selected to be any number from 7-10, 7-15, 7-20, 7-25, 7-30, 7-35, 7-40,
7-45, 7-50, 7-55, or in successive increments of 5 for the upper limit of the range, up to and
including 7-155. In other embodiments, N is selected to be any number from 8-10, 8-15, 8-20,
8-25, 8-30, 8-35, 8-40, 8-45, 8-50, 8-55, or in successive increments of 5 for the upper limit of
the range, up to and including 8-155. In other embodiments, N is selected to be any number
from 9-15, 9-20, 9-25, 9-30, 9-35, 9-40, 9-45, 9-50, 9-55, or in successive increments of 5 for
the upper limit of the range, up to and including 9-155. In other embodiments, N is selected to
be any number from 10-15, 10-20, 10-25, 10-30, 10-35, 10-40, 10-45, 10-50, 10-55, or in
successive increments of 5 for the upper limit of the range, up to and including 10-155. It will
be appreciated that N can be selected to encompass similar, but higher order, .
In one embodiment, the number of biomarkers useful for a biomarker subset or
panel is based on the sensitivity and specificity value for the particular combination of
biomarker values. The terms "sensitivity" and "specificity" are used herein with respect to the
ability to correctly classify an individual, based on one or more biomarker values detected in
their biological sample, as having an increased risk of having a CV Event within 5 years or not
having increased risk of having a CV event within the same time period. tivity" indicates
the performance of the biomarker(s) with respect to correctly classifying individuals that have
sed risk of a CV event. "Specificity" indicates the performance of the biomarker(s) with
respect to correctly fying individuals who do not have increased risk of a CV event. For
example, 85% specificity and 90% ivity for a panel of markers used to test a set of Event
Negative samples and Event Positive samples indicates that 85% of the control samples were
correctly classified as Event Negative samples by the panel, and 90% of the Event Positive
samples were correctly classified as Event Positive samples by the panel.
In an ate method, scores may be reported on a continuous range, with a
threshold of high, intermediate or low risk of a CV event, with olds determined based on
clinical findings.
The CV event risk biomarkers identified herein represent a exceedingly large
number of choices for subsets or panels of biomarkers that can be used to predict the risk of a
CV event. Selection of the desired number of such biomarkers depends on the ic
combination of kers chosen. It is important to remember that panels of biomarkers for
predicting CV event risk may also include biomarkers not found in Table 1, Col. 7, and that the
ion of additional biomarkers not found in Table 1, Col. 7 may reduce the number of
biomarkers in the particular subset or panel that is selected from Table 1, Col. 7. The number of
biomarkers from Table 1, Col. 7 used in a subset or panel may also be reduced if additional
biomedical information is used in conjunction with the biomarker values to establish
acceptable threshold values for a given assay.
Another factor that can affect the number of kers to be used in a subset or
panel of biomarkers is the procedures used to obtain biological s from individuals who
are being assessed for risk of a CV event. In a lly controlled sample ement
environment, the number of biomarkers necessary to meet desired sensitivity and specificity
and/or old values will be lower than in a situation where there can be more variation in
sample collection, handling and storage.
] One aspect of the instant application can be described generally with reference
to Figures 1A and IB. A biological sample is obtained from an individual or individuals of
interest. The biological sample is then assayed to detect the presence of one or more (N)
kers of interest and to determine a biomarker value for each of said N biomarkers
(referred to in Figure IB as marker RFU). Once a biomarker has been detected and a biomarker
value assigned each marker is scored or classified as described in detail herein. The marker
scores are then combined to provide a total diagnostic score, which indicates the likelihood that
the individual from whom the sample was obtained has high, medium or low risk of a CV
event, particularly when reported on a continuous range.
"Biological sample", "sample", and "test sample" are used hangeably
herein to refer to any material, biological fluid, tissue, or cell obtained or otherwise derived
from an individual. This includes blood (including whole blood, ytes, peripheral blood
mononuclear cells, buffy coat, plasma, and serum), dried blood spots (e.g., obtained from
infants), sputum, tears, mucus, nasal , nasal aspirate, , urine, semen, ,
peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid,
pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, bronchial
brushing, synovial fluid, joint aspirate, organ secretions, cells, a cellular t, and
cerebrospinal fluid. This also includes experimentally separated fractions of all of the
ing. For example, a blood sample can be onated into serum, plasma or into
fractions containing particular types of blood cells, such as red blood cells or white blood cells
(leukocytes). If desired, a sample can be a ation of samples from an individual, such as
a combination of a tissue and fluid sample. The term "biological sample" also includes
als containing homogenized solid material, such as from a stool sample, a tissue sample,
or a tissue biopsy, for example. The term "biological sample" also includes materials derived
from a tissue culture or a cell culture. Any suitable methods for obtaining a biological sample
can be employed; exemplary s include, e.g., phlebotomy, swab (e.g., buccal swab), and
a fine needle aspirate biopsy procedure. Exemplary tissues susceptible to fine needle aspiration
include lymph node, lung, lung washes, BAL (bronchoalveolar lavage),thyroid, breast,
pancreas and liver. Samples can also be collected, e.g., by micro dissection (e.g., laser capture
micro dissection (LCM) or laser micro dissection (LMD)), bladder wash, smear (e.g., a PAP
smear), or ductal lavage. A "biological sample" obtained or derived from an individual
includes any such sample that has been processed in any suitable manner after being obtained
from the individual.
r, it should be realized that a biological sample can be derived by taking
biological samples from a number of individuals and pooling them or pooling an aliquot of
each individual's biological sample. The pooled sample can be treated as a sample from a
single individual and if an increased or decreased risk of a CV event is established in the pooled
sample, then each individual ical sample can be re-tested to determine which
individual/s have an increased or decreased risk of a CV event.
As mentioned above, the biological sample can be urine. Urine samples
provide certain advantages over blood or serum s. Collecting blood or plasma samples
through venipuncture is more complex than is desirable, can r variable volumes, can be
worrisome for the patient, and involves some (small) risk of infection. Also, phlebotomy
requires skilled personnel. The city of collecting urine samples can lead to more
widespread application of the subject s.
In order to determine the suitability of using urine as a sample, such samples
from healthy ts were assessed for quality and quantity of each protein, and this
information was combined with the quality of the Tables 1-3 biomarkers in CV risk sis.
e urine is an ultra-filtrate of plasma, the quantity of a specific protein excreted in urine is
proportional to the protein concentration in blood. If quality biomarkers of any of Tables 1-3
are available in ient quantity in the urine, then they are suitable for use in a method for
screening an individual for evaluation of risk of a CV event. Biomarkers predictive of a CV
event that have been found in urine include ESAM, MMP7, and GP6, which show a strong
signal. These biomarkers are smaller and are freely ed by the kidney into the urine. In
on, PSA-ACT and Plasminogen have been found to demonstrate variability between
individuals in urine. This indicates that the quantification of these kers in urine can
also be useful in the method of screening an individual for risk of a CV event. Thus, these five
proteins provide for a simple urine-based test to be used in the subject methods of ing
individuals for risk of a CV event.
For purposes of this specification, the phrase "data attributed to a biological
sample from an individual" is ed to mean that the data in some form derived from, or
were generated using, the biological sample of the individual. The data may have been
reformatted, revised, or mathematically altered to some degree after having been generated,
such as by conversion from units in one measurement system to units in another measurement
system; but, the data are understood to have been derived from, or were generated using, the
biological sample.
"Target", t molecule", and "analyte" are used interchangeably herein to
refer to any molecule of interest that may be present in a biological sample. A "molecule of
interest" includes any minor variation of a particular le, such as, in the case of a protein,
for e, minor ions in amino acid sequence, disulfide bond formation, glycosylation,
lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as
conjugation with a labeling component, which does not substantially alter the identity of the
molecule. A t molecule", "target", or "analyte" is a set of copies of one type or species of
molecule or multi-molecular structure. "Target molecules", "targets", and "analytes" refer to
more than one such set of molecules. Exemplary target molecules include proteins,
polypeptides, nucleic acids, carbohydrates, lipids, polysaccharides, glycoproteins, hormones,
receptors, antigens, antibodies, affybodies, dy mimics, viruses, pathogens, toxic
substances, substrates, metabolites, tion state analogs, cofactors, inhibitors, drugs, dyes,
nutrients, growth factors, cells, tissues, and any fragment or portion of any of the ing.
As used herein, "polypeptide," "peptide," and "protein" are used
interchangeably herein to refer to polymers of amino acids of any length. The polymer may be
linear or branched, it may comprise modified amino acids, and it may be interrupted by
non-amino acids. The terms also encompass an amino acid r that has been modified
naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation,
ation, phosphorylation, or any other manipulation or modification, such as conjugation
with a labeling component. Also included within the definition are, for example, polypeptides
containing one or more analogs of an amino acid (including, for example, unnatural amino
acids, etc.), as well as other modifications known in the art. Polypeptides can be single chains
or associated chains. Also included within the tion are preproteins and intact mature
proteins; peptides or polypeptides derived from a mature protein; fragments of a protein; splice
variants; recombinant forms of a protein; protein ts with amino acid modifications,
deletions, or substitutions; digests; and post-translational cations, such as ylation,
acetylation, phosphorylation, and the like.
[001 10] As used herein, "marker" and "biomarker" are used hangeably to refer to a
target molecule that indicates or is a sign of a normal or abnormal process in an individual or of
a disease or other condition in an individual. More specifically, a "marker" or "biomarker" is
an anatomic, physiologic, biochemical, or molecular ter associated with the presence of
a specific physiological state or s, whether normal or abnormal, and, if abnormal,
whether chronic or acute. kers are detectable and measurable by a variety of methods
including laboratory assays and medical imaging. When a biomarker is a protein, it is also
possible to use the expression of the corresponding gene as a surrogate measure of the amount
or presence or absence of the corresponding protein biomarker in a biological sample or
methylation state of the gene encoding the biomarker or proteins that control expression of the
biomarker.
[001 11] As used herein, "biomarker value", "value", "biomarker level", and "level" are
used interchangeably to refer to a measurement that is made using any analytical method for
detecting the biomarker in a biological sample and that indicates the presence, absence,
absolute amount or tration, relative amount or concentration, titer, a level, an sion
level, a ratio of measured , or the like, of, for, or corresponding to the biomarker in the
biological sample. The exact nature of the "value" or "level" depends on the ic design
and ents of the particular analytical method employed to detect the biomarker.
[001 12] When a biomarker indicates or is a sign of an abnormal process or a disease or
other condition in an individual, that biomarker is generally described as being either
over-expressed or expressed as compared to an expression level or value of the
biomarker that indicates or is a sign of a normal process or an absence of a disease or other
condition in an individual. "Up-regulation", "up-regulated", expression",
"over-expressed", and any variations f are used interchangeably to refer to a value or
level of a biomarker in a biological sample that is greater than a value or level (or range of
values or levels) of the biomarker that is typically detected in similar biological samples from
healthy or normal individuals. The terms may also refer to a value or level of a biomarker in a
biological sample that is greater than a value or level (or range of values or levels) of the
biomarker that may be detected at a ent stage of a particular disease.
"Down-regulation", "down-regulated", "under-expression", "under-expressed",
and any variations thereof are used hangeably to refer to a value or level of a biomarker in
a biological sample that is less than a value or level (or range of values or levels) of the
biomarker that is lly detected in r biological samples from healthy or normal
individuals. The terms may also refer to a value or level of a biomarker in a biological sample
that is less than a value or level (or range of values or levels) of the ker that may be
detected at a different stage of a ular disease.
[001 14] Further, a biomarker that is either over-expressed or under-expressed can also
be referred to as being "differentially expressed" or as having a "differential level" or
"differential value" as compared to a "normal" expression level or value of the biomarker that
indicates or is a sign of a normal process or an absence of a disease or other condition in an
individual. Thus, "differential expression" of a biomarker can also be referred to as a variation
from a "normal" expression level of the biomarker.
[001 15] The term "differential gene expression" and "differential expression" are used
interchangeably to refer to a gene (or its corresponding protein expression product) whose
expression is activated to a higher or lower level in a subject suffering from a specific disease
or condition, relative to its expression in a normal or control subject. The terms also include
genes (or the corresponding protein expression products) whose expression is activated to a
higher or lower level at different stages of the same disease or condition. It is also tood
that a differentially expressed gene may be either activated or inhibited at the nucleic acid level
or protein level, or may be subject to alternative splicing to result in a different polypeptide
product. Such differences may be evidenced by a variety of changes including mRNA levels,
surface expression, secretion or other partitioning of a polypeptide. Differential gene
expression may include a comparison of expression between two or more genes or their gene
products; or a comparison of the ratios of the expression between two or more genes or their
gene products; or even a comparison of two differently processed products of the same gene,
which differ between normal subjects and subjects suffering from a disease; or between various
stages of the same disease. Differential expression es both quantitative, as well as
qualitative, differences in the temporal or cellular expression pattern in a gene or its expression
products among, for example, normal and diseased cells, or among cells which have undergone
different disease events or disease stages.
[001 16] As used herein, "individual" refers to a test subject or patient. The individual
can be a mammal or a non-mammal. In various ments, the individual is a . A
mammalian individual can be a human or non-human. In various embodiments, the dual
is a human. A y or normal dual is an individual in which the e or condition of
interest (including, for example, Cardiovascular Events such as myocardial infarction, stroke
and congestive heart failure) is not detectable by conventional diagnostic methods.
[001 17] "Diagnose", osing", "diagnosis", and variations f refer to the
detection, determination, or ition of a health status or condition of an individual on the
basis of one or more signs, symptoms, data, or other information pertaining to that individual.
The health status of an dual can be sed as y / normal (i.e., a diagnosis of the
absence of a disease or condition) or diagnosed as ill / abnormal (i.e., a diagnosis of the
presence, or an ment of the characteristics, of a disease or condition). The terms
"diagnose", "diagnosing", "diagnosis", etc., encompass, with t to a particular disease or
condition, the l detection of the disease; the characterization or classification of the
disease; the detection of the progression, remission, or recurrence of the disease; and the
detection of disease response after the administration of a treatment or therapy to the
individual. The prediction of risk of a CV event es distinguishing individuals who have
an increased risk of a CV event from individuals who do not.
[001 18] "Prognose", "prognosing", "prognosis", and variations thereof refer to the
prediction of a future course of a disease or condition in an individual who has the e or
condition (e.g., predicting patient survival), and such terms encompass the evaluation of
disease or condition response after the administration of a treatment or therapy to the
individual.
[001 19] "Evaluate", "evaluating", "evaluation", and variations thereof encompass both
"diagnose" and "prognose" and also encompass inations or predictions about the future
course of a disease or condition in an individual who does not have the disease as well as
determinations or predictions ing the risk that a disease or condition will recur in an
individual who apparently has been cured of the disease or has had the ion resolved. The
term "evaluate" also encompasses assessing an individual's se to a therapy, such as, for
example, predicting whether an individual is likely to respond favorably to a eutic agent
or is unlikely to respond to a therapeutic agent (or will experience toxic or other rable
side effects, for example), ing a therapeutic agent for administration to an individual, or
monitoring or determining an individual's response to a therapy that has been administered to
the individual. Thus, "evaluating" risk of a CV vent can include, for example, any of the
following: predicting the future risk of a CV event in an individual; predicting the risk of a CV
event in an individual who apparently has no CV issues; or ining or predicting an
individual's se to a CV treatment or selecting a CV treatment to administer to an
individual based upon a determination of the biomarker values derived from the individual's
biological sample. Evaluation of risk of a CV event can include embodiments such as the
assessment of risk of a CV event on a continuous scale, or classification of risk of a CV event in
escalating classifications. Classification of risk includes, for example, fication into two
or more classifications such as "No Elevated Risk of a CV Event" and "Elevated Risk of a CV
Event." The evaluation of risk of a CV event is for a defined period; such period can be, for
example, 5 years.
As used herein, "additional biomedical information" refers to one or more
evaluations of an individual, other than using any of the biomarkers described herein, that are
associated with CV risk or, more ically, CV event risk. "Additional biomedical
information" includes any of the ing: physical descriptors of an individual, including the
height and/or weight of an individual; the age of an individual; the gender of an individual;
change in weight; the ethnicity of an individual; occupational history; family history of
cardiovascular disease (or other circulatory system ers); the presence of a genetic
marker(s) correlating with a higher risk of cardiovascular disease (or other circulatory system
disorders) in the dual or a family member alterations in the carotid intima thickness;
clinical symptoms such as chest pain, weight gain or loss gene expression values; physical
descriptors of an dual, including physical descriptors observed by radiologic imaging;
smoking status; alcohol use history; occupational history; dietary habits - salt, saturated fat and
cholesterol intake; caffeine consumption; and g information such as electrocardiogram,
echocardiography, carotid ultrasound for intima-media thickness, flow mediated dilation, pulse
wave velocity, ankle -brachial index, stress rdiography, myocardial perfusion imaging,
coronary calcium by CT, high resolution CT angiography, MRI g, and other imaging
modalities ; and the dual 's medications . Testing of biomarker levels in combination with
an evaluation of any additional ical information, including other laboratory tests (e.g.,
HDL, LDL testing, CRP levels, Nt-proBNP testing , serum albumin testing, creatine testing),
may, for example, improve sensitivity, specificity, and/or AUC for prediction of CV events as
compared to biomarker testing alone or evaluating any ular item of additional biomedical
information alone (e.g., carotid intima thickness imaging alone). Additional biomedical
information can be obtained from an individual using routine techniques known in the art, such
as from the individual themselves by use of a routine patient questionnaire or health history
questionnaire, etc., or from a medical practitioner, etc. Testing of biomarker levels in
combination with an evaluation of any onal biomedical information may, for example,
improve sensitivity, specificity, and/or thresholds for tion of CV events (or other
cardiovascular-related uses) as compared to biomarker testing alone or evaluating any
particular item of additional ical information alone (e.g., CT imaging alone).
As used herein, "detecting" or "determining" with respect to a biomarker value
includes the use of both the instrument required to observe and record a signal corresponding to
a biomarker value and the material/s ed to generate that signal. In various embodiments,
the ker value is detected using any suitable method, including fluorescence,
chemiluminescence, surface plasmon resonance, surface ic waves, mass ometry,
infrared spectroscopy, Raman spectroscopy, atomic force copy, scanning tunneling
microscopy, electrochemical detection methods, nuclear magnetic resonance, quantum dots,
and the like.
"Solid support" refers herein to any substrate having a surface to which
molecules may be attached, directly or indirectly, through either covalent or non-covalent
bonds. A "solid support" can have a variety of physical formats, which can include, for
example, a membrane; a chip (e.g., a protein chip); a slide (e.g., a glass slide or coverslip); a
column; a hollow, solid, semi-solid, pore- or cavity- containing particle, such as, for example, a
bead; a gel; a fiber, including a fiber optic material; a matrix; and a sample receptacle.
Exemplary sample receptacles include sample wells, tubes, capillaries, vials, and any other
vessel, groove or indentation capable of holding a sample. A sample receptacle can be
contained on a sample platform, such as a iter plate, slide, microfluidics device,
and the like. A t can be composed of a natural or synthetic material, an organic or
inorganic material. The composition of the solid support on which capture reagents are
attached generally depends on the method of attachment (e.g., covalent attachment). Other
exemplary receptacles include microdroplets and microfluidic controlled or bulk oil/aqueous
ons within which assays and related manipulations can occur. Suitable solid supports
include, for example, cs, resins, polysaccharides, silica or silica-based materials,
functionalized glass, modified silicon, , metals, nic s, membranes, nylon,
natural fibers (such as, for example, silk, wool and cotton), polymers, and the like. The material
ing the solid support can include reactive groups such as, for example, carboxy, amino,
or hydroxyl groups, which are used for attachment of the capture reagents. Polymeric solid
supports can include, e.g., polystyrene, hylene glycol tetraphthalate, polyvinyl acetate,
polyvinyl chloride, polyvinyl pyrrolidone, rylonitrile, polymethyl methacrylate,
trafluoroethylene, butyl rubber, ebutadiene rubber, natural rubber, polyethylene,
polypropylene, (poly)tetrafluoroethylene, (poly)vinylidenefluoride, polycarbonate, and
polymethylpentene. Suitable solid support particles that can be used include, e.g., encoded
particles, such as x®-type encoded particles, magnetic particles, and glass les.
Exemplary Uses of Biomarkers
In s exemplary ments, methods are provided for evaluating risk of
a CV event in an individual by detecting one or more biomarker values corresponding to one or
more biomarkers that are present in the circulation of an individual, such as in serum or plasma,
by any number of analytical methods, ing any of the analytical methods described herein.
These biomarkers are, for example, differentially expressed in individuals with increased risk
of a CV event as compared to individuals without increased risk of a CV event. Detection of the
ential sion of a biomarker in an individual can be used, for example, to permit the
prediction of risk of a CV event within 5 year time frame.
In on to testing biomarker levels as a stand-alone diagnostic test,
biomarker levels can also be done in conjunction with determination of SNPs or other genetic
lesions or variability that are indicative of increased risk of susceptibility of disease or
condition. (See, e.g., Amos et al., Nature Genetics 40, 616-622 ).
In addition to testing biomarker levels as a stand-alone diagnostic test,
biomarker levels can also be used in conjunction with radiologic screening. Biomarker levels
can also be used in conjunction with relevant symptoms or genetic g. Detection of any of
the biomarkers described herein may be useful after the risk of CV event has been evaluated to
guide appropriate clinical care of the individual, including increasing to more aggressive levels
of care in high risk individuals after the CV event risk has been determined. In on to
testing biomarker levels in conjunction with relevant symptoms or risk factors, information
regarding the biomarkers can also be evaluated in conjunction with other types of data,
particularly data that indicates an individual's risk for cardiovascular events (e.g., patient
clinical history, symptoms, family history of cardiovascular disease, history of g or
alcohol use, risk factors such as the presence of a genetic marker(s), and/or status of other
biomarkers, etc.). These various data can be assessed by automated s, such as a
computer program/software, which can be ed in a computer or other apparatus/device.
In addition to testing biomarker levels in conjunction with ogic screening
in high risk individuals (e.g., assessing biomarker levels in conjunction with blockage detected
in a coronary angiogram), information regarding the biomarkers can also be evaluated in
conjunction with other types of data, ularly data that indicates an individual's risk for
having a CV event (e.g., patient clinical history, ms, family history of cardiovascular
e, risk factors such as r or not the individual is a smoker, heavy alcohol user
and/or status of other biomarkers, etc.). These various data can be assessed by automated
methods, such as a computer m/software, which can be embodied in a computer or other
apparatus/device.
Testing of biomarkers can also be ated with guidelines and cardiovascular
risk algorithms currently in use in clincal practice. For example, the Framingham Risk score
uses the following risk factors to result in a risk score: vascular tone, LDL-cholesterol and
HDL-cholesterol levels, impaired glucose levels, smoking, systolic blood re, and
diabetes. The frequency of high-risk patients increases with age, and men comprise a greater
proportion of high-risk patients than women.
Any of the described biomarkers may also be used in imaging tests. For
e, an imaging agent can be d to any of the bed biomarkers, which can be
used to aid in prediction of risk of a Cardiovascular Event, to monitor e to therapeutic
interventions, to select for target populations in a clinical trial among other uses.
Detection and ination of Biomarkers and Biomarker Values
A ker value for the biomarkers described herein can be detected using
any of a variety of known analytical s. In one embodiment, a ker value is
detected using a capture t. As used herein, a "capture agent" or "capture reagent" refers
to a molecule that is capable of binding specifically to a biomarker. In various embodiments,
the capture reagent can be exposed to the biomarker in solution or can be exposed to the
biomarker while the capture reagent is immobilized on a solid support. In other embodiments,
the capture reagent contains a feature that is reactive with a secondary feature on a solid
support. In these embodiments, the capture reagent can be exposed to the biomarker in
solution, and then the feature on the capture reagent can be used in conjunction with the
secondary feature on the solid support to immobilize the biomarker on the solid support. The
capture reagent is selected based on the type of analysis to be conducted. Capture reagents
e but are not limited to SOMAmers, antibodies, adnectins, ns, other antibody
mimetics and other n scaffolds, autoantibodies, chimeras, small molecules, an F(ab')2
fragment, a single chain antibody fragment, an Fv fragment, a single chain Fv fragment, a
nucleic acid, a lectin, a ligand-binding receptor, affybodies, nanobodies, imprinted polymers,
avimers, peptidomimetics, a hormone receptor, a cytokine or, and synthetic receptors,
and modifications and fragments of these.
In some embodiments, a biomarker value is detected using a biomarker/capture
reagent complex.
In other embodiments, the biomarker value is d from the
biomarker/capture reagent complex and is detected indirectly, such as, for example, as a result
of a reaction that is subsequent to the biomarker/capture reagent interaction, but is dependent
on the ion of the biomarker/capture reagent complex.
In some embodiments, the biomarker value is detected directly from the
biomarker in a biological sample.
[001 33] In one embodiment, the biomarkers are detected using a multiplexed format that
allows for the simultaneous detection of two or more biomarkers in a ical sample. In one
embodiment of the multiplexed format, capture ts are immobilized, directly or
indirectly, covalently or non-covalently, in discrete locations on a solid support. In r
embodiment, a multiplexed format uses discrete solid supports where each solid t has a
unique capture reagent associated with that solid support, such as, for example quantum dots.
In another embodiment, an individual device is used for the detection of each one of multiple
biomarkers to be detected in a biological sample. Individual devices can be configured to
permit each biomarker in the biological sample to be processed simultaneously. For example, a
microtiter plate can be used such that each well in the plate is used to uniquely analyze one of
multiple biomarkers to be detected in a biological .
In one or more of the foregoing embodiments, a fluorescent tag can be used to
label a component of the biomarker/capture complex to enable the detection of the biomarker
value. In various embodiments, the fluorescent label can be ated to a capture reagent
specific to any of the biomarkers described herein using known techniques, and the fluorescent
label can then be used to detect the corresponding biomarker value. Suitable fluorescent labels
include rare earth chelates, fluorescein and its derivatives, rhodamine and its derivatives,
dansyl, allophycocyanin, PBXL-3, Qdot 605, Lissamine, phycoerythrin, Texas Red, and other
such compounds.
[001 35] In one embodiment, the fluorescent label is a scent dye molecule. In some
embodiments, the fluorescent dye le includes at least one substituted indolium ring
system in which the substituent on the 3-carbon of the indolium ring contains a chemically
reactive group or a conjugated substance. In some embodiments, the dye molecule es an
AlexFluor molecule, such as, for example, AlexaFluor 488, AlexaFluor 532, AlexaFluor 647,
luor 680, or AlexaFluor 700. In other embodiments, the dye molecule includes a first
type and a second type of dye le, such as, e.g., two different luor molecules. In
other embodiments, the dye molecule includes a first type and a second type of dye molecule,
and the two dye molecules have different emission spectra.
Fluorescence can be measured with a y of instrumentation compatible
with a wide range of assay formats. For example, spectrofluorimeters have been designed to
analyze microtiter plates, microscope slides, printed arrays, cuvettes, etc. See Principles of
Fluorescence Spectroscopy, by J.R. cz, Springer Science + Business Media, Inc., 2004.
See Bioluminescence & Chemiluminescence: Progress & Current Applications; Philip E.
y and Larry J . Kricka editors, World Scientific hing Company, January 2002.
In one or more of the foregoing embodiments, a uminescence tag can
ally be used to label a component of the biomarker/capture complex to enable the
detection of a biomarker value. le chemiluminescent materials include any of oxalyl
chloride, Rodamin 6G, Ru(bipy)32+ , TMAE (tetrakis(dimethylamino)ethylene), Pyrogallol
-trihydroxibenzene), Lucigenin, peroxyoxalates, Aryl oxalates, Acridinium ,
dioxetanes, and others.
In yet other embodiments, the detection method includes an enzyme/substrate
combination that generates a detectable signal that corresponds to the biomarker value.
Generally, the enzyme catalyzes a chemical alteration of the chromogenic substrate which can
be ed using various techniques, including spectrophotometry, fluorescence, and
chemiluminescence. Suitable enzymes include, for example, luciferases, rin, malate
dehydrogenase, , horseradish peroxidase (HRPO), alkaline phosphatase,
beta-galactosidase, glucoamylase, lysozyme, glucose oxidase, galactose oxidase, and
glucosephosphate dehydrogenase, e, xanthine oxidase, lactoperoxidase,
microperoxidase, and the like.
In yet other embodiments, the detection method can be a combination of
fluorescence, chemiluminescence, radionuclide or enzyme/substrate combinations that
te a measurable signal. Multimodal signaling could have unique and advantageous
characteristics in ker assay formats.
More specifically, the biomarker values for the biomarkers bed herein can
be detected using known analytical methods including, singleplex SOMAmer assays,
lexed SOMAmer assays, singleplex or multiplexed immunoassays, mRNA expression
profiling, miRNA expression profiling, mass spectrometric analysis, histological/cytological
methods, etc. as detailed below.
Determination of Biomarker Values using r-Based Assays
Assays directed to the detection and quantification of logically
significant molecules in biological samples and other samples are important tools in scientific
ch and in the health care field. One class of such assays involves the use of a microarray
that includes one or more aptamers immobilized on a solid t. The aptamers are each
capable of binding to a target molecule in a highly specific manner and with very high affinity.
See, e.g., U.S. Patent No. 5,475,096 entitled "Nucleic Acid Ligands"; see also, e.g., U.S. Patent
No. 6,242,246, U.S. Patent No. 6,458,543, and U.S. Patent No. 6,503,715, each of which is
entitled "Nucleic Acid Ligand Diagnostic Biochip". Once the microarray is contacted with a
sample, the rs bind to their respective target molecules present in the sample and
thereby enable a determination of a biomarker value corresponding to a biomarker.
As used herein, an "aptamer" refers to a nucleic acid that has a specific binding
affinity for a target molecule. It is recognized that affinity interactions are a matter of ;
however, in this context, the "specific binding affinity" of an aptamer for its target means that
the aptamer binds to its target generally with a much higher degree of affinity than it binds to
other components in a test sample. An "aptamer" is a set of copies of one type or species of
nucleic acid molecule that has a particular nucleotide sequence. An aptamer can include any
suitable number of nucleotides, including any number of chemically modified nucleotides.
ers" refers to more than one such set of molecules. Different aptamers can have either
the same or different numbers of tides. rs can be DNA or RNA or chemically
modified nucleic acids and can be single stranded, double stranded, or contain double stranded
s, and can include higher ordered structures. An aptamer can also be a photoaptamer,
where a photoreactive or chemically reactive functional group is included in the aptamer to
allow it to be covalently linked to its corresponding target. Any of the aptamer methods
disclosed herein can include the use of two or more aptamers that specifically bind the same
target molecule. As r described below, an aptamer may include a tag. If an aptamer
includes a tag, all copies of the aptamer need not have the same tag. er, if different
aptamers each e a tag, these different aptamers can have either the same tag or a different
tag.
An aptamer can be identified using any known method, including the SELEX
process. Once identified, an aptamer can be prepared or synthesized in accordance with any
known method, including chemical synthetic s and enzymatic synthetic methods.
As used herein, a "SOMAmer" or Slow te Modified Aptamer refers to an
aptamer having improved off-rate characteristics. SOMAmers can be generated using the
improved SELEX methods described in U.S. Publication No. 2009/0004667, entitled "Method
for Generating Aptamers with Improved Off-Rates."
The terms "SELEX" and "SELEX s" are used interchangeably herein to
refer generally to a combination of (1) the selection of rs that interact with a target
molecule in a desirable manner, for example binding with high ty to a protein, with (2) the
amplification of those selected nucleic acids. The SELEX process can be used to identify
aptamers with high affinity to a specific target or biomarker.
] SELEX generally includes preparing a candidate mixture of nucleic acids,
binding of the ate mixture to the desired target molecule to form an affinity complex,
ting the affinity complexes from the unbound candidate nucleic acids, separating and
ing the nucleic acid from the affinity complex, purifying the nucleic acid, and identifying
a specific aptamer sequence. The s may include multiple rounds to further refine the
affinity of the selected aptamer. The process can include amplification steps at one or more
points in the process. See, e.g., U.S. Patent No. 5,475,096, entitled "Nucleic Acid Ligands".
The SELEX process can be used to generate an aptamer that covalently binds its target as well
as an aptamer that valently binds its target. See, e.g., U.S. Patent No. 337 ed
"Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment: Chemi-SELEX."
The SELEX process can be used to identify high-affinity aptamers containing
modified nucleotides that confer improved characteristics on the aptamer, such as, for example,
improved in vivo stability or improved ry characteristics. Examples of such
cations include chemical substitutions at the ribose and/or phosphate and/or base
positions. SELEX s-identified aptamers containing modified nucleotides are described
in U.S. Patent No. 5,660,985, entitled "High Affinity Nucleic Acid Ligands Containing
Modified Nucleotides", which describes oligonucleotides containing nucleotide derivatives
chemically modified at the 5'- and 2'-positions of pyrimidines. U.S. Patent No. 5,580,737, see
supra, describes highly specific aptamers containing one or more tides modified with
no (2'-NH2), 2'-fluoro (2'-F), and/or 2'methyl (2'-OMe). See also, U.S. Patent
Application Publication 20090098549, entitled "SELEX and PHOTOSELEX", which
describes nucleic acid libraries having expanded al and chemical properties and their use
in SELEX and ELEX.
SELEX can also be used to identify aptamers that have desirable off-rate
characteristics. See U.S. Patent Application Publication 20090004667, entitled "Method for
Generating Aptamers with Improved Off-Rates", which bes improved SELEX methods
for generating aptamers that can bind to target les. As mentioned above, these slow
off-rate aptamers are known as "SOMAmers." Methods for producing rs or
SOMAmers and photoaptamers or SOMAmers having slower rates of iation from their
respective target molecules are described. The methods involve contacting the candidate
mixture with the target molecule, allowing the formation of nucleic acid-target complexes to
occur, and performing a slow off-rate ment process wherein nucleic acid-target
xes with fast dissociation rates will dissociate and not reform, while complexes with
slow iation rates will remain intact. Additionally, the methods include the use of
modified nucleotides in the production of candidate nucleic acid mixtures to generate aptamers
or SOMAmers with improved off-rate performance.
A variation of this assay employs aptamers that include photoreactive
functional groups that enable the aptamers to covalently bind or "photocrosslink" their target
les. See, e.g., U.S. Patent No. 6,544,776 entitled "Nucleic Acid Ligand stic
Biochip". These photoreactive aptamers are also referred to as photoaptamers. See, e.g., U.S.
Patent No. 5,763,177, U.S. Patent No. 6,001,577, and U.S. Patent No. 184, each of which
is entitled "Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment:
Photoselection of Nucleic Acid Ligands and Solution SELEX"; see also, e.g., U.S. Patent No.
6,458,539, entitled "Photoselection of Nucleic Acid Ligands". After the microarray is
contacted with the sample and the photoaptamers have had an opportunity to bind to their target
molecules, the photoaptamers are photoactivated, and the solid support is washed to remove
any non-specifically bound les. Harsh wash conditions may be used, since target
molecules that are bound to the photoaptamers are generally not removed, due to the covalent
bonds created by the ctivated functional group(s) on the photoaptamers. In this ,
the assay enables the detection of a biomarker value corresponding to a biomarker in the test
In both of these assay s, the aptamers or rs are immobilized on
the solid support prior to being contacted with the sample. Under certain circumstances,
r, immobilization of the aptamers or SOMAmers prior to contact with the sample may
not provide an optimal assay. For e, pre-immobilization of the aptamers or SOMAmers
may result in inefficient mixing of the aptamers or SOMAmers with the target molecules on the
surface of the solid support, perhaps leading to lengthy reaction times and, therefore, extended
incubation periods to permit efficient binding of the aptamers or SOMAmers to their target
molecules. Further, when photoaptamers or photoSOMAmers are employed in the assay and
depending upon the material ed as a solid support, the solid support may tend to scatter or
absorb the light used to effect the formation of covalent bonds between the photoaptamers or
photoSOMAmers and their target molecules. Moreover, depending upon the method
employed, detection of target molecules bound to their aptamers or photoSOMAmers can be
subject to imprecision, since the surface of the solid support may also be exposed to and
affected by any labeling agents that are used. Finally, immobilization of the aptamers or
SOMAmers on the solid support generally involves an aptamer or SOMAmer-preparation step
(i.e., the immobilization) prior to re of the aptamers or SOMAmers to the sample, and
this ation step may affect the activity or functionality of the aptamers or SOMAmers.
SOMAmer assays that permit a SOMAmer to capture its target in solution and
then employ separation steps that are ed to remove specific components of the
SOMAmer-target mixture prior to detection have also been described (see U.S. Patent
Application Publication 20090042206, entitled "Multiplexed Analyses of Test Samples"). The
described SOMAmer assay methods enable the detection and quantification of a non-nucleic
acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid
(i.e., a SOMAmer). The described methods create a nucleic acid surrogate (i.e, the SOMAmer)
for ing and quantifying a non-nucleic acid , thus ng the wide variety of
nucleic acid technologies, including amplification, to be applied to a r range of desired
targets, including protein targets.
SOMAmers can be constructed to facilitate the separation of the assay
components from a SOMAmer biomarker complex (or photoSOMAmer biomarker covalent
complex) and permit isolation of the SOMAmer for detection and/or quantification. In one
embodiment, these constructs can include a cleavable or releasable element within the
SOMAmer ce. In other embodiments, additional functionality can be introduced into the
SOMAmer, for example, a labeled or detectable component, a spacer component, or a specific
g tag or immobilization element. For example, the SOMAmer can include a tag
connected to the SOMAmer via a cleavable moiety, a label, a spacer component separating the
label, and the cleavable moiety. In one embodiment, a cleavable element is a photocleavable
linker. The photocleavable linker can be attached to a biotin moiety and a spacer section, can
include an NHS group for tization of amines, and can be used to introduce a biotin group
to a SOMAmer, thereby allowing for the release of the r later in an assay .
Homogenous assays, done with all assay components in on, do not require
separation of sample and reagents prior to the detection of signal. These methods are rapid and
easy to use. These methods generate signal based on a molecular capture or binding reagent
that reacts with its specific . For prediction of CV events, the molecular capture reagents
would be a SOMAmer or an antibody or the like and the specific target would be a CV event
biomarker of Table 1, Col. 7.
In one embodiment, a method for signal generation takes advantage of
anisotropy signal change due to the interaction of a fluorophore-labeled capture reagent with its
specific biomarker target. When the labeled e reagent reacts with its target, the increased
molecular weight causes the rotational motion of the fluorophore attached to the x to
become much slower changing the anisotropy value. By monitoring the anisotropy change,
binding events may be used to quantitatively e the biomarkers in solutions. Other
methods include scence polarization assays, molecular beacon methods, time resolved
fluorescence quenching, chemiluminescence, fluorescence resonance energy transfer, and the
like.
An exemplary solution-based SOMAmer assay that can be used to detect a
biomarker value corresponding to a ker in a biological sample includes the following:
(a) preparing a mixture by contacting the biological sample with a SOMAmer that includes a
first tag and has a specific affinity for the biomarker, wherein a r affinity complex is
formed when the biomarker is present in the sample; (b) exposing the mixture to a first solid
support including a first capture element, and allowing the first tag to associate with the first
capture element; (c) removing any components of the mixture not associated with the first solid
support; (d) attaching a second tag to the biomarker component of the r affinity
complex; (e) ing the SOMAmer affinity complex from the first solid support; (f)
exposing the ed SOMAmer affinity complex to a second solid support that includes a
second capture element and allowing the second tag to ate with the second capture
element; (g) removing any non-complexed SOMAmer from the mixture by partitioning the
mplexed SOMAmer from the SOMAmer affinity complex; (h) eluting the SOMAmer
from the solid support; and (i) detecting the biomarker by detecting the SOMAmer component
of the SOMAmer affinity complex.
] Any means known in the art can be used to detect a biomarker value by
ing the SOMAmer ent of a SOMAmer affinity x. A number of different
ion methods can be used to detect the SOMAmer component of an affinity complex, such
as, for example, hybridization assays, mass spectroscopy, or QPCR. In some ments,
nucleic acid sequencing methods can be used to detect the SOMAmer component of a
SOMAmer affinity x and y detect a biomarker value. Briefly, a test sample can be
subjected to any kind of nucleic acid sequencing method to identify and quantify the sequence
or sequences of one or more SOMAmers present in the test sample. In some embodiments, the
sequence includes the entire SOMAmer molecule or any portion of the molecule that may be
used to uniquely identify the molecule. In other embodiments, the identifying sequencing is a
specific sequence added to the SOMAmer; such sequences are often referred to as "tags,"
des," or "zipcodes." In some embodiments, the sequencing method includes enzymatic
steps to amplify the SOMAmer sequence or to convert any kind of nucleic acid, including RNA
and DNA that contain chemical modifications to any position, to any other kind of nucleic acid
appropriate for sequencing.
In some embodiments, the sequencing method includes one or more cloning
steps. In other embodiments the sequencing method includes a direct sequencing method
t cloning.
In some embodiments, the sequencing method es a directed approach
with specific primers that target one or more SOMAmers in the test sample. In other
embodiments, the sequencing method includes a shotgun approach that targets all SOMAmers
in the test sample.
In some embodiments, the sequencing method es enzymatic steps to
amplify the molecule targeted for sequencing. In other embodiments, the sequencing method
directly sequences single molecules. An exemplary c acid cing-based method that
can be used to detect a biomarker value corresponding to a biomarker in a ical sample
includes the following: (a) converting a mixture of SOMAmers that contain chemically
modified nucleotides to unmodified nucleic acids with an tic step; (b) shotgun
sequencing the resulting unmodified nucleic acids with a massively parallel sequencing
platform such as, for example, the 454 Sequencing System (454 Life Sciences/Roche), the
Illumina Sequencing System (Illumina), the ABI SOLiD Sequencing System (Applied
Biosystems), the HeliScope Single Molecule Sequencer (Helicos Biosciences), or the Pacific
Biosciences Real Time Single-Molecule Sequencing System (Pacific Biosciences) or the
Polonator G Sequencing System (Dover s); and (c) identifying and quantifying the
SOMAmers present in the mixture by ic sequence and sequence count.
Determination of Biomarker Values using Immunoassays
Immunoassay methods are based on the reaction of an antibody to its
corresponding target or analyte and can detect the analyte in a sample depending on the specific
assay format. To improve specificity and sensitivity of an assay method based on
immuno-reactivity, monoclonal antibodies are often used because of their specific epitope
recognition. Polyclonal antibodies have also been successfully used in s immunoassays
because of their increased affinity for the target as compared to monoclonal dies.
Immunoassays have been designed for use with a wide range of biological sample es.
assay formats have been designed to provide qualitative, semi-quantitative, and
quantitative results.
Quantitative results are generated through the use of a standard curve created
with known trations of the ic e to be detected. The response or signal from
an unknown sample is plotted onto the standard curve, and a quantity or value corresponding to
the target in the unknown sample is established.
Numerous immunoassay formats have been designed. ELISA or EIA can be
quantitative for the detection of an analyte. This method relies on attachment of a label to either
the analyte or the antibody and the label component includes, either directly or indirectly, an
enzyme. ELISA tests may be formatted for direct, indirect, competitive, or sandwich detection
of the e. Other methods rely on labels such as, for example, radioisotopes (1125) or
fluorescence. Additional techniques include, for e, agglutination, nephelometry,
turbidimetry, Western blot, precipitation, immunocytochemistry,
immunohistochemistry, flow cytometry, Luminex assay, and others (see ImmunoAssay: A
Practical Guide, edited by Brian Law, hed by Taylor & Francis, Ltd., 2005 edition).
Exemplary assay formats include enzyme-linked immunosorbent assay
(ELISA), radioimmunoassay, fluorescent, chemiluminescence, and fluorescence resonance
energy transfer (FRET) or time resolved-FRET (TR-FRET) immunoassays. Examples of
procedures for detecting biomarkers include biomarker immunoprecipitation ed by
quantitative methods that allow size and peptide level discrimination, such as gel
electrophoresis, capillary electrophoresis, planar electrochromatography, and the like.
Methods of detecting and/or quantifying a detectable label or signal generating
material depend on the nature of the label. The products of reactions catalyzed by appropriate
enzymes (where the detectable label is an enzyme; see above) can be, without limitation,
fluorescent, luminescent, or radioactive or they may absorb visible or ultraviolet light.
Examples of detectors suitable for detecting such detectable labels include, without limitation,
x-ray film, radioactivity counters, llation rs, spectrophotometers, colorimeters,
fluorometers, luminometers, and densitometers.
[001 65] Any of the methods for detection can be performed in any format that allows for
any suitable preparation, processing, and analysis of the reactions. This can be, for example, in
multi-well assay plates (e.g., 96 wells or 384 wells) or using any suitable array or microarray.
Stock ons for various agents can be made manually or robotically, and all subsequent
pipetting, diluting, , distribution, washing, incubating, sample readout, data collection
and is can be done robotically using commercially available analysis software, robotics,
and ion instrumentation capable of detecting a detectable label.
Determination of Biomarker Values using Gene Expression Profiling
] Measuring mRNA in a biological sample may be used as a surrogate for
detection of the level of the corresponding n in the biological sample. Thus, any of the
kers or biomarker panels bed herein can also be detected by detecting the
appropriate RNA.
mRNA expression levels are measured by reverse transcription tative
polymerase chain reaction (RT-PCR followed with qPCR). RT-PCR is used to create a cDNA
from the mRNA. The cDNA may be used in a qPCR assay to produce fluorescence as the DNA
amplification process progresses. By comparison to a standard curve, qPCR can produce an
absolute measurement such as number of copies of mRNA per cell. Northern blots,
microarrays, Invader assays, and RT-PCR ed with ary electrophoresis have all
been used to measure expression levels of mRNA in a sample. See Gene Expression Profiling:
Methods and Protocols, Richard A. Shimkets, editor, Humana Press, 2004.
miRNA molecules are small RNAs that are non-coding but may regulate gene
expression. Any of the methods suited to the ement of mRNA expression levels can also
be used for the corresponding miRNA. Recently many laboratories have investigated the use of
miRNAs as biomarkers for disease. Many diseases involve wide-spread transcriptional
regulation, and it is not surprising that miRNAs might find a role as biomarkers. The
connection between miRNA concentrations and disease is often even less clear than the
connections between protein levels and disease, yet the value of miRNA biomarkers might be
substantial. Of course, as with any RNA expressed differentially during disease, the problems
facing the development of an in vitro diagnostic product will include the ement that the
miRNAs survive in the ed cell and are easily extracted for analysis, or that the miRNAs
are released into blood or other matrices where they must survive long enough to be measured.
n biomarkers have similar requirements, although many potential protein biomarkers are
secreted intentionally at the site of pathology and function, during disease, in a paracrine
n. Many potential protein kers are ed to on outside the cells within
which those proteins are synthesized.
Detection of Biomarkers Using In Vivo Molecular Imaging Technologies
Any of the described biomarkers (see Table 1, Col. 7) may also be used in
molecular imaging tests. For example, an imaging agent can be coupled to any of the described
biomarkers, which can be used to aid in prediction of risk of Cardiovascular Events within 5
years, to r se to therapeutic interventions, to select a population for clinical trials
among other uses.
In vivo imaging technologies provide vasive methods for determining the
state of a particular disease or condition in the body of an individual. For example, entire
ns of the body, or even the entire body, may be viewed as a three dimensional image,
thereby providing valuable information concerning morphology and structures in the body.
Such technologies may be combined with the detection of the biomarkers described herein to
provide information ning the cardiovascular status of an individual.
The use of in vivo molecular imaging technologies is expanding due to s
advances in logy. These advances include the development of new contrast agents or
labels, such as radiolabels and/or scent labels, which can provide strong signals within
the body; and the pment of powerful new imaging technology, which can detect and
analyze these signals from outside the body, with sufficient sensitivity and accuracy to provide
useful information. The contrast agent can be visualized in an riate imaging system,
thereby providing an image of the portion or portions of the body in which the contrast agent is
located. The contrast agent may be bound to or associated with a capture reagent, such as a
SOMAmer or an antibody, for example, and/or with a peptide or protein, or an oligonucleotide
(for example, for the detection of gene expression), or a complex containing any of these with
one or more macromolecules and/or other particulate forms.
The contrast agent may also feature a radioactive atom that is useful in imaging.
le radioactive atoms include technetium-99m or iodine- 123 for scintigraphic studies.
Other readily detectable moieties include, for example, spin labels for magnetic resonance
imaging (MRI) such as, for example, -123 again, iodine-131, indium-Ill, fluorine-19,
carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron. Such labels are well
known in the art and could easily be selected by one of ordinary skill in the art.
rd imaging techniques e but are not limited to magnetic resonance
imaging, computed tomography scanning (coronary calcium score), positron emission
tomography (PET), single photon emission computed tomography ), computed
tomography angiography, and the like. For diagnostic in vivo imaging, the type of detection
instrument available is a major factor in selecting a given contrast agent, such as a given
radionuclide and the particular biomarker that it is used to target in, mRNA, and the like).
The uclide chosen typically has a type of decay that is able by a given type of
instrument. Also, when selecting a radionuclide for in vivo diagnosis, its ife should be
long enough to enable detection at the time of maximum uptake by the target tissue but short
enough that deleterious radiation of the host is minimized.
] Exemplary imaging techniques include but are not limited to PET and SPECT,
which are imaging techniques in which a radionuclide is synthetically or locally administered
to an individual. The uent uptake of the radiotracer is measured over time and used to
obtain information about the targeted tissue and the biomarker. Because of the high-energy
(gamma-ray) emissions of the specific isotopes employed and the sensitivity and sophistication
of the instruments used to detect them, the two-dimensional distribution of radioactivity may
be inferred from e of the body.
Commonly used positron-emitting nuclides in PET include, for example,
carbon-11, nitrogen-13, oxygen-15, and fluorine-18. es that decay by on capture
and/or gamma-emission are used in SPECT and e, for example iodine- 123 and
technetium-99m. An exemplary method for labeling amino acids with technetium-99m is the
reduction of pertechnetate ion in the ce of a chelating precursor to form the labile
technetium-99m-precursor complex, which, in turn, reacts with the metal binding group of a
bifunctionally modified chemotactic peptide to form a technetium-99m-chemotactic peptide
conjugate.
Antibodies are frequently used for such in vivo imaging diagnostic methods.
The ation and use of antibodies for in vivo diagnosis is well known in the art. Labeled
antibodies which ically bind any of the biomarkers in Table 1, Col. 7 can be injected into
an individual suspected of having an increased risk of a CV event, detectable according to the
particular biomarker used, for the purpose of diagnosing or evaluating the disease status or
condition of the individual. The label used will be selected in accordance with the imaging
modality to be used, as previously described. zation of the label permits determination of
the tissue damage or other indications related to the risk of a CV event. The amount of label
within an organ or tissue also allows ination of the involvement of the CV event
biomarkers due to the risk of a CV event in that organ or tissue.
Similarly, SOMAmers may be used for such in vivo imaging diagnostic
methods. For example, a SOMAmer that was used to identify a particular biomarker described
in Table 1, Col. 7 (and ore binds specifically to that particular biomarker) may be
appropriately labeled and ed into an individual suspected of having had a CV event,
detectable according to the particular biomarker, for the purpose of diagnosing or evaluating
the levels of tissue damage, atherosclerotic plaques, components of inflammatory response and
other factors ated with the risk of a CV event in the individual. The label used will be
ed in accordance with the g modality to be used, as previously described.
Localization of the label s determination of the site of the processes leading to increased
risk. The amount of label within an organ or tissue also allows determination of the infiltration
of the pathological process in that organ or tissue. SOMAmer-directed imaging agents could
have unique and advantageous characteristics relating to tissue penetration, tissue distribution,
kinetics, elimination, potency, and selectivity as compared to other imaging agents.
Such techniques may also ally be performed with labeled
ucleotides, for example, for detection of gene expression through imaging with antisense
ucleotides. These methods are used for in situ hybridization, for example, with
scent les or radionuclides as the label. Other methods for detection of gene
expression include, for example, detection of the activity of a reporter gene.
Another general type of imaging technology is optical imaging, in which
fluorescent signals within the subject are detected by an optical device that is external to the
subject. These signals may be due to actual fluorescence and/or to bioluminescence.
Improvements in the sensitivity of optical detection devices have increased the usefulness of
optical imaging for in vivo diagnostic assays.
The use of in vivo lar biomarker imaging is increasing, including for
clinical , for example, to more rapidly e clinical efficacy in trials for new disease or
condition therapies and/or to avoid prolonged treatment with a placebo for those diseases, such
as multiple sclerosis, in which such prolonged treatment may be ered to be ethically
questionable.
For a review of other techniques, see N . Blow, Nature Methods, 6, 465-469,
2009.
Determination of Biomarker Values using Mass Spectrometry Methods
A variety of configurations of mass spectrometers can be used to detect
biomarker values. Several types of mass spectrometers are available or can be produced with
various configurations. In general, a mass spectrometer has the following major components: a
sample inlet, an ion source, a mass analyzer, a or, a vacuum system, and
instrument-control system, and a data system. Difference in the sample inlet, ion source, and
mass analyzer generally define the type of instrument and its capabilities. For example, an inlet
can be a capillary-column liquid chromatography source or can be a direct probe or stage such
as used in matrix-assisted laser desorption. Common ion sources are, for example,
electrospray, including nanospray and pray or matrix-assisted laser desorption.
Common mass analyzers include a quadrupole mass filter, ion trap mass analyzer and
time-of-flight mass er. Additional mass spectrometry methods are well known in the art
(see Burlingame et al. Anal. Chem. 70:647 R-716R ; Kinter and Sherman, New York
Protein biomarkers and biomarker values can be detected and measured by any
of the following: electrospray ionization mass spectrometry (ESI-MS), ESI-MS/MS,
ESI-MS/(MS)n, matrix-assisted laser desorption ionization time-of-flight mass spectrometry
(MALDI-TOF-MS), surface-enhanced laser desorption/ionization time-of-flight mass
spectrometry (SELDI-TOF-MS), desorption/ionization on silicon (DIOS), secondary ion mass
spectrometry (SIMS), quadrupole time-of-flight ), tandem time-of-flight (TOF/TOF)
technology, called ultraflex III TOF/TOF, atmospheric pressure chemical ionization mass
spectrometry (APCI-MS), APCI-MS/MS, APCI-(MS)N, atmospheric pressure
photoionization mass spectrometry MS), APPI-MS/MS, and APPI-(MS)N, quadrupole
mass spectrometry, Fourier transform mass spectrometry (FTMS), quantitative mass
spectrometry, and ion trap mass ometry.
Sample preparation gies are used to label and enrich samples before mass
oscopic characterization of protein biomarkers and determination biomarker values.
Labeling s include but are not limited to isobaric tag for relative and absolute
quantitation (iTRAQ) and stable isotope labeling with amino acids in cell culture (SILAC).
Capture reagents used to ively enrich samples for candidate biomarker ns prior to
mass spectroscopic analysis include but are not limited to SOMAmers, antibodies, nucleic acid
probes, as, small molecules, an F(ab')2 fragment, a single chain antibody nt, an
Fv fragment, a single chain Fv fragment, a nucleic acid, a lectin, a ligand-binding receptor,
affybodies, nanobodies, ankyrins, domain antibodies, alternative antibody scaffolds (e.g.
diabodies etc) imprinted polymers, avimers, omimetics, peptoids, peptide nucleic acids,
threose nucleic acid, a hormone receptor, a cytokine or, and synthetic receptors, and
cations and fragments of these.
Determination of Biomarker Values using a Proximity Ligation Assay
A proximity ligation assay can be used to ine biomarker values. Briefly,
a test sample is contacted with a pair of affinity probes that may be a pair of antibodies or a pair
of SOMAmers, with each member of the pair extended with an oligonucleotide. The targets for
the pair of affinity probes may be two distinct determinates on one protein or one determinate
on each of two different proteins, which may exist as homo- or hetero-multimeric complexes.
When probes bind to the target determinates, the free ends of the oligonucleotide extensions are
brought into sufficiently close proximity to hybridize er. The hybridization of the
oligonucleotide extensions is facilitated by a common connector oligonucleotide which serves
to bridge together the oligonucleotide ions when they are positioned in ient
proximity. Once the oligonucleotide extensions of the probes are hybridized, the ends of the
extensions are joined together by enzymatic DNA ligation.
Each oligonucleotide extension comprises a primer site for PCR amplification.
Once the oligonucleotide extensions are ligated together, the ucleotides form a
continuous DNA ce which, through PCR amplification, reveals information regarding
the ty and amount of the target protein, as well as, information regarding protein-protein
interactions where the target determinates are on two different proteins. ity ligation can
provide a highly sensitive and ic assay for real-time n concentration and interaction
information through use of real-time PCR. Probes that do not bind the determinates of interest
do not have the corresponding oligonucleotide extensions t into proximity and no
ligation or PCR amplification can proceed, resulting in no signal being produced.
[001 87] The foregoing assays enable the detection of biomarker values that are useful in
methods for prediction of risk of CV events, where the methods comprise detecting, in a
biological sample from an individual, at least N biomarker values that each pond to a
biomarker selected from the group consisting of the biomarkers provided in Table 1, Col. 7,
wherein a classification, as described in detail below, using the biomarker values indicates
whether the individual has elevated risk of a CV event occuring within a 5 year time period.
While certain of the described CV event biomarkers are useful alone for predicting risk of a CV
event, methods are also described herein for the grouping of multiple subsets of the CV event
biomarkers that are each useful as a panel of three or more biomarkers. Thus, various
embodiments of the instant application provide combinations comprising N biomarkers,
wherein N is at least three biomarkers. In other embodiments, N is selected to be any number
from 2-155 biomarkers. It will be appreciated that N can be selected to be any number from any
of the above described ranges, as well as similar, but higher order, ranges. In accordance with
any of the methods described herein, biomarker values can be detected and classified
individually or they can be detected and classified collectively, as for example in a multiplex
assay format.
A biomarker "signature" for a given diagnostic or predictive test contains a set
of markers, each marker having different levels in the tions of interest. ent ,
in this context, may refer to different means of the marker levels for the individuals in two or
more groups, or ent variances in the two or more groups, or a combination of both. For the
simplest form of a stic test, these markers can be used to assign an n sample
from an individual into one of two groups, either at increased risk of a CV event or not. The
assignment of a sample into one of two or more groups is known as classification, and the
procedure used to accomplish this assignment is known as a classifier or a classification
method. Classification methods may also be ed to as g methods. There are many
classification methods that can be used to construct a diagnostic classifier from a set of
biomarker values. In general, classification methods are most easily performed using
supervised learning techniques where a data set is collected using samples obtained from
individuals within two (or more, for multiple classification states) distinct groups one wishes to
distinguish. Since the class (group or population) to which each sample belongs is known in
advance for each sample, the classification method can be d to give the desired
classification response. It is also possible to use unsupervised learning techniques to produce a
diagnostic classifier.
Common approaches for developing diagnostic classifiers e decision
trees; bagging, boosting, forests and random forests; rule inference based learning; Parzen
Windows; linear models; logistic; neural network methods; unsupervised clustering; K-means;
hierarchical ascending/ ding; semi-supervised learning; prototype methods; nearest
neighbor; kernel y estimation; t vector machines; hidden Markov ;
Boltzmann Learning; and classifiers may be combined either simply or in ways which
ze particular objective functions. For a review, see, e.g., Pattern Classification, R.O.
Duda, et al., editors, John Wiley & Sons, 2nd edition, 2001; see also, The Elements of
Statistical Learning - Data Mining, Inference, and Prediction, T. Hastie, et al., editors, Springer
Science+Business Media, LLC, 2nd edition, 2009; each of which is incorporated by reference
in its entirety.
To produce a classifier using supervised learning techniques, a set of samples
called training data are obtained. In the context of diagnostic tests, training data includes
samples from the distinct groups (classes) to which unknown samples will later be assigned.
For example, samples collected from individuals in a l population and duals in a
particular disease, condition or event population can constitute training data to p a
classifier that can classify unknown samples (or, more particularly, the duals from whom
the samples were obtained) as either having the disease, condition or elevated risk of an event
or being free from the disease, condition or elevated risk of an event. The development of the
classifier from the training data is known as training the classifier. Specific details on classifier
training depend on the nature of the supervised learning que (see, e.g., Pattern
Classification, R.O. Duda, et al., s, John Wiley & Sons, 2nd edition, 2001; see also, The
Elements of Statistical ng - Data Mining, Inference, and Prediction, T. Hastie, et al.,
editors, er Science+Business Media, LLC, 2nd n, 2009).
] Since typically there are many more potential biomarker values than samples in
a ng set, care must be used to avoid over-fitting. Over-fitting occurs when a statistical
model describes random error or noise instead of the underlying relationship. Over-fitting can
be avoided in a variety of ways, including, for example, by limiting the number of markers
used in developing the classifier, by assuming that the marker responses are ndent of one
another, by limiting the complexity of the ying statistical model employed, and by
ensuring that the underlying statistical model conforms to the data.
[001 92] In order to identify a set of biomarkers associated with occurence of , the
combined set of l and early event samples were analyzed using pal Component
Analysis (PCA). PCA displays the samples with respect to the axes defined by the strongest
variations between all the samples, without regard to the case or control outcome, thus
mitigating the risk of overfitting the distinction n case and control. Since the occurrence
of s thrombotic events has a strong component of chance involved, requiring unstable
plaque to rupture in vital vessels to be reported, one would not expect to see a clear separation
between the control and event sample sets. While the observed separation between case and
control is not large, it occurs on the second principal ent, corresponding to around 10%
of the total variation in this set of samples, which indicates that the underlying biological
ion is relatively simple to quantify (Figure 2A).
] In the next set of analyses, biomarkers can be analyzed for those components of
difference between samples which were specific to the separation n the control samples
and early event samples. One method that may be employed is the use of DSGA (Bair,E. and
Tibshirani,R. (2004) Semi-supervised methods to predict patient survival from gene expression
data. PLOS Biol., 2, 5 11-522) to remove te) the first three principal component
directions of variation between the samples in the control set. gh the dimensionality
reduction is performed on the control set to discover, both the samples in the control and the
samples from the early event samples are run through the PCA. Separation of cases from early
events can be observed along the horizontal axis (Figure 2B).
Cross validated selection of proteins relevant to cardiovascular risk
In order to avoid over-fitting of protein predictive power to idiosyncratic
features of a particular selection of samples, a cross-validation and dimensional reduction
approach was taken. Cross-validation involves the multiple selection of sets of samples to
ine the association of risk by protein combined with the use of the unselected samples to
monitor the y of the method to apply to s which were not used in producing the
model of risk (The Elements of Statistical Learning - Data Mining, Inference, and Prediction,
T. Hastie, et al., editors, Springer Science+Business Media, LLC, 2nd edition, 2009). We
applied the ised PCA method of Tibshirani et al (Bair,E. and Tibshirani,R. (2004)
Semi-supervised methods to predict patient survival from gene sion data. PLOS Biol., 2,
11-522.) which is applicable to high dimensional datasets in the modeling of event risk. The
supervised PCA (SPCA) method s the univariate selection of a set of ns
statistically associated with the observed event hazard in the data and the determination of the
correlated component which es information from all of these proteins. This
determination of the correlated component is a dimensionality reduction step which not only
combines information across ns, but also mitigates the likelihood of overfitting by
ng the number of independent variables from the full protein menu of over 1000 proteins
down to a few principal components (in this work, we only examined the first principal
component). The SPCA method of Tibshirani et al. applies cross validation to the selection of
proteins in order to determine the number of proteins which are truly predictive in the withheld
cross-validation test sets. These proteins are used to create the correlated component of protein
variation associated with event risk. Using SPCA we found a list of 155 proteins which were
statistically associated with event risk using this cross-validated dimensional reduction
que. In this ation of SPCA, we also allowed test protein signals corresponding to
random SOMAmer sequences as well as signals corresponding to nonhuman proteins, which
were not present in the samples. None of these 10-20 known nonbiological signals were
selected in the 155 proteins by SPCA (Table 1). This step using the cross-validated SPCA
approach is ant to screen against false positive protein marker associations. The
approach in rani et al is especially protected against false discovery by the use of
prevalidation method of cross-validation and the dimensional reduction inherent in PCA. The
list of 155 proteins from SPCA was used to check subsequent analyses using different
techniques to detect the false discovery of protein markers, not contained in the list of 155
proteins from SPCA.
Univariate is and multivariate analysis of the relationship of individual proteins to time
to event
[001 95] The Cox proportional hazard model (Cox, David R ( 1972). "Regression Models
and Life-Tables". Journal of the Royal Statistical y. Series B (Methodological) 34 (2):
187-220.)) is widely used in medical statistics. Cox regression avoids fitting a specific function
of time to the cumulative survival, and instead employs a model of ve risk referred to a
baseline hazard function (which may vary with time). The baseline hazard function describes
the common shape of the survival time distribution for all individuals, while the relative risk
gives the level of the hazard for a set of covariate values (such as a single individual or group),
as a multiple of the ne hazard. The relative risk is constant with time in the Cox model.
We fitted 1092 simple univariate Cox models to all signals. 46 proteins (Table
2) have P-values (Wald test, (Wald, m. . A Method of Estimating Plane
Vulnerability Based on Damage of Survivors. Statistical Research Group, Columbia
University) better than 10 14 . All of these 46 proteins were included in the list of 155 proteins
selected using SPCA (above, Table 1). The large number of highly significant proteins is at
first surprising, however the involvement of the kidney in the cardiovascular disease implies
s in GFR (Glomerular filtration rate). Decreases in GFR will increase all proteins with
non-zero renal clearance, the concentration of a protein in the blood is reduced through loss of
the protein into the urine via the kidney (clearance), reduced renal filtration as ed by
GFR is thus associated with sed concentration of those ns in the blood which are
lly filtered by the kidney.
A useful model would be more parsimonious than the full list of 46 proteins.
Also as seen in the PCA many ns are likely to be highly correlated, an effective model
will take this into account. We filtered the list of 46 highly significant proteins down to 10
proteins in two steps. First, we restricted the list to the 20 proteins which gave a coefficient
with a magnitude greater than 0.37 (equivalent to a 30% hazard change for a doubling in
protein signal), this step was taken on a single ariate Cox model using all 46 proteins.
(The natural log of the protein measurements were taken before fitting the Cox models,
therefore exponential of the Cox coefficient corresponds to the hazard ratio of an e-fold (2.71)
change in the protein measurement.)
The next step filtered the 20 proteins down to ten by ing that the p-value
should be more significant than 0.01. This step suppresses covariant proteins and allows
ndent proteins to contribute. A final adjustment was made to the biomarker ion in
that C9, a member of the membrane attack complex in the final common pathway of the
complement system, was judged to be too unspecific in its signaling, a matter which cannot be
decided from this study alone, since the study is created to cleanly demonstrate Cardio vascular
risk. C9 was removed and all the remaining proteins were evaluated in its place. The substitute
proteins were ranked on the improvement in the Wald test score, and KLK3.SerpinA3 was
close to as effective as C9.
The Kaplan Meier survival curves are shown in Figures 3A-3E for this ten
marker model of cardiovascular risk.
Table 1 identifies 155 biomarkers that are useful for evaluation the risk of a
future CV event in an individual. This is a surprisingly larger number than expected when
compared to what is typically found during biomarker discovery efforts and may be
attributable to the scale of the described study, which encompassed over 1000 proteins
measured in hundreds of individual samples, in some cases at concentrations in the low
olar range. Presumably, the large number of discovered biomarkers reflects the diverse
biochemical pathways ated in the biology leading up to a cardiovascular event and the
body's response to the CV event; each pathway and process involves many proteins. The
results show that no single protein of a small group of proteins is uniquely informative about
such x ses; rather, that multiple proteins are involved in relevant processes, such
as GFR, atherosclerosis, inflammation and hormonal CV regulation, for example.
The s from Example 2 suggest certain possible conclusions: First, the
identification of a large number of biomarkers enables their aggregation into a vast number of
classifiers that offer similarly high performance. Second, classifiers can be constructed such
that particular biomarkers may be substituted for other kers in a manner that reflects the
redundancies that undoubtedly pervade the xities of the underlying e, condition or
event processes. That is to say, the information about the disease, condition or event
contributed by any individual biomarker identified in Table 1 overlaps with the information
contributed by other biomarkers, such that it may be that no particular biomarker or small
group of biomarkers in Table 1 must be included in any classifier.
Kits
Any combination of the biomarkers of Table 1, Col. 7 can be detected using a
suitable kit, such as for use in performing the methods sed herein. Furthermore, any kit
can contain one or more detectable labels as bed herein, such as a fluorescent , etc.
In one embodiment, a kit includes (a) one or more capture reagents (such as, for
example, at least one SOMAmer or antibody) for detecting one or more biomarkers in a
biological sample, wherein the biomarkers include any of the biomarkers set forth in Table 1,
Col. 7, and optionally (b) one or more software or computer program ts for classifying
the individual from whom the biological sample was obtained as either having or not having
increased risk of a CV event or for ining the likelihood that the individual has increased
risk of a CV event, as further described herein. atively, rather than one or more er
program products, one or more instructions for manually performing the above steps by a
human can be provided.
The combination of a solid support with a corresponding capture reagent having
a signal generating material is referred to herein as a "detection device" or "kit". The kit can
also include instructions for using the devices and reagents, ng the sample, and analyzing
the data. Further the kit may be used with a computer system or software to analyze and report
the result of the analysis of the ical sample.
The kits can also contain one or more reagents (e.g., solubilization buffers,
detergents, washes, or s) for processing a biological sample. Any of the kits described
herein can also include, e.g., buffers, blocking agents, mass spectrometry matrix materials,
antibody capture agents, positive control samples, negative control samples, software and
information such as protocols, guidance and reference data.
In one aspect, the invention provides kits for the analysis of CV event risk
. The kits include PCR primers for one or more SOMAmers specific to biomarkers
selected from Table 1, Col. 7. The kit may r include instructions for use and correlation of
the biomarkers with prediction of risk of a CV event. The kit may also include a DNA array
containing the complement of one or more of the Somamers specific for the biomarkers
selected from Table 1, Col. 7, reagents, and/or enzymes for amplifying or isolating sample
DNA. The kits may include reagents for real-time PCR, for example, TaqMan probes and/or
s, and enzymes.
For example, a kit can comprise (a) reagents comprising at least capture reagent
for quantifying one or more biomarkers in a test sample, wherein said biomarkers comprise the
kers set forth in Table 1, Col. 7, or any other biomarkers or kers panels described
herein, and optionally (b) one or more thms or computer programs for performing the
steps of comparing the amount of each biomarker quantified in the test sample to one or more
predetermined cutoffs and assigning a score for each ker quantified based on said
comparison, combining the assigned scores for each biomarker quantified to obtain a total
score, comparing the total score with a predetermined score, and using said comparison to
determine whether an individual has an sed risk of a CV event. Alternatively, rather than
one or more algorithms or computer programs, one or more ctions for manually
ming the above steps by a human can be provided.
Computer Methods and re
Once a ker or biomarker panel is selected, a method for diagnosing an
individual can comprise the following: 1) collect or otherwise obtain a biological sample; 2)
perform an analytical method to detect and measure the biomarker or biomarkers in the panel in
the biological sample; 3) perform any data normalization or standardization required for the
method used to collect biomarker values; 4) calculate the marker score; 5) combine the marker
scores to obtain a total diagnostic or predictive score; and 6) report the individual's diagnostic
or predictive score. In this approach, the diagnostic or predictive score may be a single number
determined from the sum of all the marker calculations that is compared to a preset threshold
value that is an indication of the presence or absence of disease. Or the diagnostic or predictive
score may be a series of bars that each represent a biomarker value and the pattern of the
responses may be compared to a pre-set pattern for determination of the ce or absence of
disease, condition or the sed risk (or not) of an event.
At least some embodiments of the methods described herein can be
implemented with the use of a computer. An example of a computer system 100 is shown in
Figure 4 . With reference to Figure 4, system 100 is shown comprised of hardware elements that
are electrically d via bus 108, including a processor 101, input device 102, output device
103, storage device 104, er-readable storage media reader 105a, ications
system 106, processing acceleration (e.g., DSP or special-purpose processors) 107 and
memory 109. Computer-readable e media reader 105a is further coupled to
computer-readable storage media 105b, the combination comprehensively representing
remote, local, fixed and/or removable storage devices plus storage media, memory, etc. for
temporarily and/or more permanently containing er-readable information, which can
include e device 104, memory 109 and/or any other such accessible system 100 resource.
System 100 also comprises software elements (shown as being currently located within
working memory 191) including an operating system 192 and other code 193, such as
programs, data and the like.
With respect to Figure 4, system 100 has extensive flexibility and
configurability. Thus, for example, a single architecture might be utilized to implement one or
more servers that can be r configured in accordance with currently desirable protocols,
protocol variations, ions, etc. However, it will be apparent to those d in the art that
embodiments may well be ed in accordance with more specific application requirements.
For example, one or more system elements might be implemented as sub-elements within a
system 100 component (e.g., within communications system 106). Customized hardware might
also be utilized and/or particular elements might be implemented in hardware, software or
both. Further, while connection to other computing devices such as network input/output
s (not shown) may be employed, it is to be understood that wired, wireless, modem,
and/or other connection or connections to other computing devices might also be utilized.
[0021 1] In one aspect, the system can comprise a database containing features of
kers characteristic of prediction of risk of a CV event. The biomarker data (or biomarker
ation) can be utilized as an input to the computer for use as part of a computer
implemented method. The biomarker data can include the data as described .
In one aspect, the system further comprises one or more devices for providing
input data to the one or more processors.
The system further ses a memory for storing a data set of ranked data
elements.
In another aspect, the device for providing input data comprises a detector for
detecting the characteristic of the data t, e.g., such as a mass spectrometer or gene chip
reader.
The system additionally may comprise a database management system. User
requests or queries can be formatted in an appropriate language understood by the database
management system that processes the query to extract the relevant information from the
database of training sets.
The system may be connectable to a k to which a network server and one
or more clients are connected. The network may be a local area network (LAN) or a wide area
network (WAN), as is known in the art. Preferably, the server includes the hardware necessary
for running computer program products (e.g., software) to access database data for processing
user requests.
The system may include an operating system (e.g., UNIX or Linux) for
executing instructions from a database management . In one aspect, the operating
system can operate on a global communications k, such as the internet, and utilize a
global communications network server to connect to such a network.
The system may include one or more s that comprise a graphical display
ace comprising interface elements such as buttons, pull down menus, scroll bars, fields
for entering text, and the like as are routinely found in graphical user interfaces known in the
art. Requests entered on a user interface can be transmitted to an application m in the
system for formatting to search for relevant information in one or more of the system
databases. ts or queries d by a user may be constructed in any suitable database
language.
[002 19] The graphical user interface may be ted by a graphical user interface code
as part of the operating system and can be used to input data and/or to display inputted data.
The result of processed data can be displayed in the interface, printed on a printer in
communication with the system, saved in a memory device, and/or transmitted over the
network or can be provided in the form of the computer readable medium.
The system can be in communication with an input device for providing data
regarding data elements to the system (e.g., expression values). In one aspect, the input device
can include a gene expression profiling system including, e.g., a mass spectrometer, gene chip
or array reader, and the like.
The s and apparatus for analyzing CV event risk prediction biomarker
information according to various embodiments may be implemented in any suitable ,
for example, using a computer program operating on a er system. A conventional
er system comprising a processor and a random access , such as a
remotely-accessible application server, network server, personal computer or ation may
be used. onal computer system components may include memory devices or information
storage systems, such as a mass storage system and a user interface, for example a conventional
monitor, keyboard and tracking device. The computer system may be a stand-alone system or
part of a network of computers including a server and one or more databases.
The CV event risk prediction biomarker analysis system can e functions
and operations to complete data analysis, such as data ing, processing, analysis,
reporting and/or diagnosis. For e, in one embodiment, the computer system can execute
the er program that may receive, store, search, analyze, and report information relating
to the CV event risk prediction biomarkers. The computer program may comprise multiple
modules performing various functions or operations, such as a processing module for
processing raw data and generating supplemental data and an analysis module for analyzing
raw data and supplemental data to generate a CV event risk prediction status and/or diagnosis
or risk calculation. Calculation of risk status for a CV event may optionally comprise
generating or collecting any other information, including additional biomedical information,
regarding the condition of the individual relative to the disease, condition or event, identifying
whether further tests may be desirable, or otherwise evaluating the health status of the
individual.
Referring now to Figure 5, an example of a method of utilizing a computer in
accordance with principles of a disclosed embodiment can be seen. In Figure 5, a flowchart
3000 is shown. In block 3004, biomarker information can be retrieved for an individual. The
biomarker information can be retrieved from a er database, for example, after testing of
the dual's biological sample is med. The biomarker information can comprise
biomarker values that each correspond to one of at least N biomarkers selected from a group
consisting of the biomarkers provided in Table 1 , Col. 7, wherein N = 2-155. In block 3008, a
computer can be ed to classify each of the biomarker values. And, in block 3012, a
determination can be made as to the likelihood that an individual has increased risk of a CV
event based upon a plurality of classifications. The indication can be output to a display or
other indicating device so that it is viewable by a person. Thus, for example, it can be displayed
on a display screen of a computer or other output device.
Referring now to Figure 6, an alternative method of utilizing a computer in
ance with another embodiment can be illustrated via flowchart 3200. In block 3204, a
computer can be utilized to retrieve biomarker information for an individual. The biomarker
information comprises a ker value corresponding to a biomarker selected from the
group of biomarkers provided in Table 1 , Col.7. In block 3208, a classification of the
biomarker value can be performed with the computer. And, in block 3212, an indication can be
made as to the likelihood that the individual has increaseed risk of a CV event based upon the
classification. The indication can be output to a y or other indicating device so that it is
viewable by a . Thus, for example, it can be displayed on a display screen of a computer
or other output device.
Some embodiments described herein can be implemented so as to include a
computer program product. A computer program t may include a computer readable
medium having computer readable program code embodied in the medium for causing an
ation program to execute on a computer with a database.
As used herein, a "computer program t" refers to an organized set of
instructions in the form of natural or programming language statements that are contained on a
physical media of any nature (e.g., written, electronic, magnetic, optical or otherwise) and that
may be used with a computer or other automated data processing . Such programming
language statements, when executed by a computer or data processing system, cause the
computer or data processing system to act in accordance with the particular content of the
statements. Computer m products include without tion: programs in source and
object code and/or test or data libraries ed in a computer readable medium.
Furthermore, the computer program product that enables a er system or data processing
equipment device to act in pre-selected ways may be provided in a number of forms, including,
but not limited to, original source code, assembly code, object code, e language,
encrypted or compressed versions of the foregoing and any and all equivalents.
] In one aspect, a computer program product is provided for tion of the risk
of a CV event. The er program product includes a computer readable medium
embodying program code executable by a processor of a computing device or system, the
program code comprising: code that ves data attributed to a biological sample from an
individual, n the data comprises ker values that each correspond to one of at least
N biomarkers in the biological sample selected from the group of biomarkers provided in Table
1, Col. 7, wherein N = 2-155; and code that es a classification method that indicates a CV
event risk status of the individual as a function of the biomarker values.
In still another aspect, a computer program product is ed for indicating a
likelihood of risk of a CV event. The computer program product includes a computer readable
medium embodying program code executable by a processor of a computing device or system,
the program code comprising: code that retrieves data attributed to a biological sample from an
individual, wherein the data comprises a biomarker value corresponding to a biomarker in the
biological sample selected from the group of biomarkers provided in Table 1 , Col. 7; and code
that executes a classification method that indicates a CV event risk status of the individual as a
function of the biomarker value.
While various embodiments have been described as methods or tuses, it
should be understood that embodiments can be implemented through code coupled with a
computer, e.g., code resident on a computer or ible by the er. For example,
software and databases could be ed to implement many of the methods discussed above.
Thus, in addition to embodiments accomplished by hardware, it is also noted that these
embodiments can be accomplished through the use of an article of manufacture comprised of a
computer usable medium having a computer readable program code embodied therein, which
causes the enablement of the functions disclosed in this description. Therefore, it is desired that
embodiments also be considered protected by this patent in their program code means as well.
Furthermore, the ments may be embodied as code stored in a computer-readable
memory of virtually any kind including, without limitation, RAM, ROM, magnetic media,
optical media, or magneto-optical media. Even more lly, the embodiments could be
implemented in software, or in re, or any combination thereof including, but not limited
to, software running on a general purpose sor, microcode, PLAs, or ASICs.
It is also envisioned that embodiments could be lished as computer
signals embodied in a carrier wave, as well as signals (e.g., electrical and optical) propagated
through a transmission . Thus, the various types of information discussed above could
be formatted in a structure, such as a data structure, and transmitted as an ical signal
through a transmission medium or stored on a computer readable medium.
[0023 1] It is also noted that many of the structures, materials, and acts recited herein can
be d as means for performing a function or step for performing a function. Therefore, it
should be understood that such language is ed to cover all such ures, materials, or
acts disclosed within this specification and their equivalents, including the matter incorporated
by reference.
The biomarker identification process, the utilization of the biomarkers disclosed
herein, and the s methods for determining biomarker values are described in detail above
with respect to evaluation of risk of a CV event. However, the application of the process, the
use of identified biomarkers, and the methods for determining biomarker values are fully
applicable to other ic types of cardiovascular conditions, to any other disease or medical
condition, or to the fication of individuals who may or may not be benefited by an
ancillary medical treatment.
EXAMPLES
The following examples are ed for illustrative purposes only and are not
intended to limit the scope of the application as defined by the appended claims. All examples
described herein were carried out using standard ques, which are well known and routine
to those of skill in the art. Routine molecular biology techniques described in the ing
examples can be carried out as described in standard laboratory manuals, such as Sambrook et
al., Molecular Cloning: A Laboratory Manual, 3rd. ed., Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, N.Y., (2001).
Example 1. Multiplexed Aptamer Analysis of Samples
This example describes the multiplex aptamer assay used to analyze the
samples and controls for the identification of the biomarkers set forth in Table 1. The general
protocol for is of a sample is illustrated in Figures 1A and IB. ly in medical
studies of survival data, the Cox proportional hazard model is employed to produce a risk score
from multiple covariates of pathological state. In this work, we have employed this simple and
well known approach to devise a model from the population data in the Heart and Soul study,
for example, le for application to individual samples according to this flexible and widely
used Cox Proportional Hazard Formalism. The biomarker values are combined as shown in
Figure IB by taking the log ratio of the biomarker measurements relative to the normal .
The Cox model uses the exponential of the weighted sum of these log ratios to produce an
estimate of the hazard ratio to the normal population.
In this method, pipette tips were changed for each on addition.
] Also, unless otherwise indicated, most solution transfers and wash additions
used the 96-well head of a Beckman Biomek FxP. Method steps manually pipetted used a
twelve channel P200 Pipetteman (Rainin Instruments, LLC, Oakland, CA), unless otherwise
indicated. A custom buffer referred to as SB 17 was prepared in-house, comprising 40mM
HEPES, lOOmM NaCl, 5mM KC1, 5mM MgC12, ImM EDTA at pH7.5. All steps were
performed at room ature unless otherwise indicated.
1. Preparation of Aptamer Stock Solution
Custom stock aptamer solutions for 5%, 0.316% and 0.01% serum were
prepared at 2x concentration in l x SB 17, 0.05% Tween-20.
These solutions are stored at -20°C until use. The day of the assay, each aptamer mix was
thawed at 37°C for 10 minutes, placed in a boiling water bath for 10 minutes and allowed to
cool to 25°C for 20 minutes with vigorous mixing in between each heating step. After
heat-cool, 55m1of each 2x aptamer mix (was manually pipetted into a 96-well Hybaid plate and
the plate foil sealed. The final result was three, 96-well, foil-sealed Hybaid plates with 5%,
0.316% or 0.01% aptamer mixes. The individual aptamer concentration was 2x final or 1 nM.
2. Assay Sample Preparation
Frozen aliquots of 100% serum, stored at -80°C, were placed in 25°C water bath
for 10 minutes. Thawed samples were placed on ice, gently vortexed (set on 4) for 8 seconds
and then replaced on ice.
A 10% sample solution (2x final) was prepared by transferring 8 m of sample
using a 50 m 8-channel ng pipettor into 96-well Hybaid , each well ning 72
of the appropriate sample diluent at 4°C (lx SB17, 0.06% Tween-20, I I .ImM Z-block_2,
0.44 mM MgCl 2, 2.2mM AEBSF, l.lmM EGTA, 55.6uM EDTA for serum). This plate was
stored on ice until the next sample dilution steps were initiated on the Biomek FxP robot.
To commence sample and aptamer equilibration, the 10% sample plate was
y centrifuged and placed on the Biomek FxP where it was mixed by ing up and
down with the 96-well pipettor. A -0.632% sample plate (2x final) was then prepared by
transferring 6mE of the 10% sample plate into 89 mE of lxSB 17, 0.05% Tween-20 with 2mM
AEBSF. Next, dilution of 6 mE of the resultant 0.632% sample into 184 mE of lxSB 17, 0.05%
Tween-20 made a 0.02% sample plate (2x final). Dilutions were done on the Beckman Biomek
FxP. After each er, the solutions were mixed by pipetting up and down. The 3 sample
dilution plates were then transferred to their respective aptamer solutions by adding 55 mE of
the sample to 55 m of the appropriate 2x aptamer mix. The sample and aptamer solutions were
mixed on the robot by pipetting up and down.
3. Sample Equilibration binding
The sample/aptamer plates were sealed with silicon cap mats and placed into a
37°C incubator for 3.5 hours before proceeding to the Catch 1 step.
4. Preparation of Catch 2 bead plate
An 11 mL aliquot of MyOne (Invitrogen Corp., ad, CA) Streptavidin CI
beads was washed 2 times with equal volumes of 20 mM NaOH (5 minute incubation for each
wash), 3 times with equal volumes of l x SB17, 0.05% Tween-20 and resuspended in 11 mL l x
SB17, 0.05% Tween-20. Using a nnel pipettor, 50 m of this solution was manually
pipetted into each well of a 96-well Hybaid plate. The plate was then covered with foil and
stored at 4°C for use in the assay.
. Preparation of Catch 1 bead plates
Three 0.45 mih Millipore HV plates (Durapore ne, Cat# MAHVN4550)
were equilibrated with 100 m of l x SB 17, 0.05% Tween-20 for at least 10 s. The
equilibration buffer was then filtered through the plate and 133.3 m of a 7.5%
Streptavidin-agarose bead slurry (in l x SB17, 0.05% Tween-20) was added into each well. To
keep the streptavidin-agarose beads suspended while transferring them into the filter plate, the
bead solution was manually mixed with a 200 m , nnel pipettor, at least 6 times between
pipetting events. After the beads were buted across the 3 filter plates, a vacuum was
applied to remove the bead supernatant. Finally, the beads were washed in the filter plates with
200 l x SB17, 0.05% Tween-20 and then resuspended in 200 l x SB17, 0.05%
Tween-20. The bottoms of the filter plates were blotted and the plates stored for use in the
assay.
6. Loading the Cytomat
] The cytomat was loaded with all tips, plates, all reagents in troughs (except
otin reagent which was prepared fresh right before addition to the plates), 3 prepared
catch 1 filter plates and 1 prepared MyOne plate.
7. Catch 1
After a 3.5 hour equilibration time, the sample/aptamer plates were d
from the incubator, centrifuged for about 1 minute, cap mat covers removed, and placed on the
deck of the Beckman Biomek FxP. The Beckman Biomek FxP program was initiated. All
subsequent steps in Catch 1 were performed by the Beckman Biomek FxP robot unless
otherwise noted. Within the m, the vacuum was applied to the Catch 1 filter plates to
remove the bead supernatant. One hundred microlitres of each of the 5%, 0.316% and 0.01%
equilibration binding reactions were added to their respective Catch 1 filtration plates, and each
plate was mixed using an on-deck orbital shaker at 800 rpm for 10 minutes.
Unbound solution was removed via vacuum filtration. The Catch 1 beads were
washed with 190 ΐ of 100 mM biotin in l x SB17, 0.05% Tween-20 followed by 5x 190 ΐ of
l x SB17, 0.05% 20 by dispensing the solution and immediately drawing a vacuum to
filter the solution h the plate.
8. Tagging
] A lOOmM NHS-PE04-biotin aliquot in anhydrous DMSO (stored at -20°C)
was thawed at 37°C for 6 minutes and then was diluted 1:100 with tagging buffer (SB 17 at
pH=7.25, 0.05% Tween-20), immediately before manual on to an k trough
whereby the robot dispensed 100 m of the NHS-PE04-biotin into each well of each Catch 1
filter plate. This on was allowed to incubate with Catch 1 beads shaking at 800 rpm for 5
minutes on the orbital shakers.
9. Kinetic nge and Photo-cleavage
The tagging reaction was removed by vacuum filtration and the reaction
quenched by the addition of 150 m of 20 mM glycine in l x SB17, 0.05% Tween-20 to the
Catch 1 plates The glycine solution was removed via vacuum filtrationand another 1500m of
mM glycine (in l x SB17, 0.05% Tween-20) was added to each plate and incubated for 1
minute on orbital shakers at 800 rpm before removal by vacuum filtration.
The wells of the Catch 1 plates were uently washed by adding 190 m l x
SB17, 0.05% Tween-20, followed immediately by vacuum filtration and then by adding 190
m l x SB 17, 0.05% Tween-20 with shaking for 1 minute at 800 rpm before vacuum filtration.
These two wash steps were repeated two more times with the exception that the last wash was
not removed by vacuum filtration. After the last wash the plates were placed on top of a 1 mL
deep-well plate and removed from the deck for centrifugation at 1000 rpm for 1 minute to
remove as much extraneous volume from the agarose beads before elution as possible.
The plates were placed back onto the Beckman Biomek FxP and 85 of 10
mM DxS04 in l x SB 17, 0.05% Tween-20 was added to each well of the filter plates.
[0025 1] The filter plates were removed from the deck, placed onto a Variomag
shaker (Thermo Fisher Scientific, Inc., Waltham, MA ) under the BlackRay (Ted Pella,
Inc., Redding, CA) light sources, and irradiated for 5 s while shaking at 800 rpmAfter
the 5-minute incubation the plates were rotated 180 degrees and irradiated with shaking for 5
minutes more.
] The photocleaved solutions were sequentially eluted from each Catch 1 plate
into a common deep well plate by first placing the 5% Catch 1 filter plate on top of a 1 mL
deep-well plate and centrifuging at 1000 rpm for 1 minute. The 0.316% and 0.01% Catch 1
plates were then sequentially centrifuged into the same deep well plate.
. Catch 2 bead capture
The 1 mL deep well block containing the combined eluates of Catch 1 was
placed on the deck of the n Biomek FxP for Catch 2 .
The robot transferred all of the photo-cleaved eluate from the 1 mL deep-well
plate onto the Hybaid plate containing the previously prepared Catch 2 MyOne magnetic beads
(after l of the MyOne buffer via magnetic tion).
The solution was incubated while shaking at 1350 rpm for 5 minutes at 25°C on
a Variomag Thermoshaker o Fisher Scientific, Inc., Waltham, MA).
The robot transferred the plate to the on deck magnetic separator station. The
plate was incubated on the magnet for 90 seconds before removal and discarding of the
supernatant.
11. 37°C 30% glycerol washes
] The Catch 2 plate was moved to the on-deck thermal shaker and 75 m of l x
SB17, 0.05% Tween-20 was transferred to each well. The plate was mixed for 1 minute at 1350
rpm and 37°C to resuspend and warm the beads. To each well of the catch 2 plate, 75 m of
60% glycerol at 37°C was transferred and the plate continued to mix for another minute at 1350
rpm and 3°C. The robot transferred the plate to the 37°C magnetic separator where it was
incubated on the magnet for 2 minutes and then the robot d and discarded the
supernatant. These washes were repeated two more times.
After removal of the third 30% glycerol wash from the Catch 2 beads, 150 m of
l x SB17, 0.05% Tween-20 was added to each well and incubated at 37°C, shaking at 1350 rpm
for 1 minute, before removal by ic tion on the 37°C magnet.
The Catch 2 beads were washed a final time using 150 l x SB 19, 0.05%
Tween-20 with incubation for 1 minute while shaking at 1350 rpm, prior to magnetic
separation.
12. Catch 2 Bead Elution and lization
The aptamers were eluted from Catch 2 beads by adding 105 m of 100 mM
CAPSO with 1 M NaCl, 0.05% Tween-20 to each well. The beads were incubated with this
solution with shaking at 1300 rpm for 5 s.
The Catch 2 plate was then placed onto the magnetic separator for 90 seconds
prior to transferring 63 m of the eluate to a new 96-well plate containing 7 of 500 mM HC1,
500 mM HEPES, 0.05% Tween-20 in each well. After transfer, the solution was mixed
robotically by pipetting 60 E up and down five times.
13. Hybridization
The Beckman Biomek FxP transferred 20 E of the neutralized Catch 2 eluate
to a fresh Hybaid plate, and 6 mE of lOx Agilent Block, containing a lOx spike of hybridization
controls, was added to each well. Next, 30 mE of 2x Agilent Hybridization buffer was manually
pipetted to the each well of the plate containing the neutralized samples and blocking buffer
and the solution was mixed by manually pipetting 25 mE up and down 15 times slowly to avoid
extensive bubble formation. The plate was spun at 1000 rpm for 1 minute.
Custom Agilent microarray slides (Agilent Technologies, Inc., Santa Clara,
CA) were designed to contain probes complementary to the aptamer random region plus some
primer region. For the majority of the aptamers, the optimal length of the complementary
sequence was empirically determined and ranged between 40-50 nucleotides. For later
rs a 46-mer complementary region was chosen by default. The probes were linked to
the slide surface with a poly-T linker for a total probe length of 60 tides.
A gasket slide was placed into an Agilent hybridization chamber and 40 mE of
each of the samples ning hybridization and blocking on was manually ed into
each gasket. An 8-channel variable spanning or was used in a manner intended to
minimize bubble formation. The custom Agilent slides, with the barcode facing up, were then
slowly lowered onto the gasket slides (see Agilent manual for detailed description).
The top of the hybridization chambers were placed onto the slide/backing
sandwich and clamping brackets slid over the whole ly. These assemblies were tightly
clamped by turning the screws securely.
Each slide/backing slide sandwich was visually inspected to assure the solution
bubble could move freely within the sample. If the bubble did not move freely the
hybridization chamber assembly was gently tapped to disengage bubbles lodged near the
gasket.
The led ization rs were ted in an Agilent
hybridization oven for 19 hours at 60°C rotating at 20 rpm.
14. Post Hybridization Washing
Approximately 400 mL Agilent Wash Buffer 1 was placed into each of two
te glass staining dishes. One of the staining dishes was placed on a magnetic stir plate
and a slide rack and stir bar were placed into the buffer.
A staining dish for Agilent Wash 2 was prepared by placing a stir bar into an
empty glass staining dish.
A fourth glass staining dish was set aside for the final itrile wash.
Each of six hybridization chambers was disassembled. One-by-one, the
slide/backing sandwich was removed from its hybridization chamber and submerged into the
ng dish containing Wash 1. The slide/backing sandwich was pried apart using a pair of
tweezers, while still submerging the microarray slide. The slide was quickly transferred into
the slide rack in the Wash 1 staining dish on the magnetic stir plate.
The slide rack was gently raised and lowered 5 times. The magnetic stirrer was
turned on at a low setting and the slides incubated for 5 minutes.
When one minute was remaining for Wash 1, Wash Buffer 2 pre-warmed to
37°C in an incubator was added to the second prepared ng dish. The slide rack was
quickly erred to Wash Buffer 2 and any excess buffer on the bottom of the rack was
removed by scraping it on the top of the stain dish. The slide rack was gently raised and
lowered 5 times. The magnetic stirrer was turned on at a low setting and the slides incubated for
minutes. The slide rack was slowly pulled out of Wash 2, taking approximately 15 seconds to
remove the slides from the solution.
With one minute remaining in Wash 2 acetonitrile (ACN) was added to the
fourth staining dish. The slide rack was transferred to the acetonitrile stain dish. The slide rack
was gently raised and lowered 5 times. The magnetic stirrer was turned on at a low setting and
the slides incubated for 5 minutes.
The slide rack was slowly pulled out of the ACN stain dish and placed on an
absorbent towel. The bottom edges of the slides were quickly dried and the slide was placed
into a clean slide box.
. rray Imaging
The microarray slides were placed into Agilent scanner slide holders and loaded
into the Agilent Microarray scanner according to the manufacturer's instructions.
The slides were imaged in the Cy3-channel at 5 mih resolution at the 100% PMT
setting and the XRD option enabled at 0.05. The resulting tiff images were processed using
Agilent feature tion software version 10.5.
Example 2. Biomarker Identification
The identification of potential CV event biomarkers was performed for
tion of risk of a CV event in a population of duals in the San Francisco Bay Area.
Participants had to meet one of the following enrollment criteria for this study: prior
myocardial infarction, raphic evidence of greater than 50% stenosis in 1 or more
coronary vessels, exercise-induced ischemia by ill or nuclear testing, or prior coronary
revascularization. Exclusion criteria included recent myocardial infarction, inability to walk
around 1 block, and plans to relocate. Fasting blood s were collected, and serum and
plasma aliquots were stored at -70°C. The multiplexed SOMAmer affinity assay as described
in Example 1 was used to measure and report the RFU value for 1034 analytes in each of
these 987 samples.
In order to identify a set of biomarkers associated with occurence of , the
combined set of control and early event samples were analyzed using PCA. PCA displays the
samples with t to the axes defined by the strongest variations between all the samples,
without regard to the case or control outcome, thus mitigating the risk of overfitting the
distinction between case and control. rol" refers to individuals who met at least one of
the entry ia, but who did not have a CV event during the course of the study; "case" refers
to individuals who met at least one of the entry ia, but who did have a CV event during the
course of the study.) While the observed separation between case and control is not large, it
occurs on the second principal component, corresponding to around 10% of the total variation
in this set of samples, which indicates that the underlying biological variation is relatively
simple to quantify (Figure 2A).
In the next set of analyses, biomarkers can be analyzed for those components of
difference between samples which were specific to the separation between the l samples
and early event samples. Although the dimensionality reduction is performed on the control set
alone, to determine the multivariate multidimensional space of variation spanned by the
ences n control samples, both the samples in the l set and the set of early
event samples are deflated for space of variation determined between control samples, the
residual variation is enriched in those components separating case from control. This is known
as the DSGA method. Separation of cases from early events can be observed along the
horizontal axis (Figure 2B) (Nicolau M, Tibshirani R, B0rresen-Dale AL, Jeffrey SS.
Disease-specific genomic analysis: Identifying the signature of pathologic biology.
Bioinformatics. 2007;23:957-965.)
In order to avoid over-fitting of protein predictive power to idiosyncratic
features of a particular selection of samples, a cross-validation and dimensional reduction
approach was taken. This determination of the correlated component is a ionality
reduction step which not only es information across proteins, but also mitigates the
likelihood of overfitting by reducing the number of independent variables from the full protein
menu of over 1000 proteins down to a few principal components (in this work, we only
ed the first principal ent). These proteins are used to create the correlated
component of protein variation ated with event risk. Using SPCA (Supervised Principal
Component Analysis) we found a list of 155 proteins which were statistically associated with
event risk using this validated ional reduction technique. In this application of
SPCA, we also allowed test n s corresponding to random SOMAmer sequences as
well as signals corresponding to non-human proteins, which were not present in the samples.
None of these 10-20 known non-biological signals were selected in the 155 ns by SPCA
(Table 1). This step using the cross-validated SPCA approach is important to screen against
false positive protein marker associations. The approach in Tibshirani et al. (Bair,E. and
Tibshirani,R. (2004) Semi-supervised methods to t patient survival from gene expression
data. PLOS Biol., 2, 5 11-522) is especially protected t false discovery by the use of
prevalidation method of cross-validation and the dimensional reduction inherent in PCA. The
list of 155 proteins from SPCA was used to check subsequent analyses using different
ques to detect the false discovery of protein markers, not contained in the list of 155
proteins from SPCA.
Example 3. Univariate Analysis of the Relationship of dual Proteins to Time to CV
Event
] The Cox proportional hazard model (Cox, David R . "Regression Models
and Life-Tables". Journal of the Royal Statistical Society. Series B (Methodological) 34 (2):
187-220)) is widely used in medical tics. Cox regression avoids fitting a specific function
of time to the cumulative survival, and instead employs a model of relative risk referred to a
ne hazard function (which may vary with time). The baseline hazard function describes
the common shape of the survival time bution for all individuals, while the relative risk
gives the level of the hazard for a set of covariate values (such as a single dual or group),
as a multiple of the baseline hazard. The relative risk is constant with time in the Cox model.
] The method involved fitting 1092 simple univariate Cox models to all signals.
Forty-six proteins have P-values (Wald, Abraham. (1943). A Method of Estimating Plane
Vulnerability Based on Damage of Survivors. Statistical Research Group, Columbia
University)) better than 10 14 . The large number of highly significant proteins is at first
surprising, however the involvement of the kidney in the cardiovascular disease implies
s in the glomerular filtration rate (GFR). Decreases in GFR will increase all proteins
with non-zero renal nce.
A useful model (in terms of technical complexity and cost in the laboratory)
would be more parsimonious than the full list of 46 proteins shown in Table 2. Also as seen in
the PCA many proteins are likely to be highly correlated; an effective model will take this into
account. The list of 46 highly icant proteins was filtered down to 10 proteins as shown in
Table 3 in two steps. Firstly, the list was restricted to the 20 proteins which gave a coefficient
with a magnitude greater than 0.37 (equivalent to a 30% hazard change for a doubling in
protein signal). This step was taken on a single multivariate Cox model using all 46 proteins.
(The natural log of the protein measurements were taken before g the Cox models.
ore the exponential of the Cox coefficient corresponds to the hazard ratio of an e-fold
(2.71) change in the protein measurement.)
The next step filtered the 20 proteins down to nine by requiring that the P-value
should be more significant than 0.01. This step suppresses covariant proteins and allows
independent proteins to contribute. A final adjustment was made to the biomarker selection in
that C9, a member of the membrane attack complex in the final common pathway of the
complement system, was judged to be too ific in its signaling, a matter which cannot be
decided from this study alone, since the study is created to cleanly demonstrate CV event risk.
C9 was removed and all the remaining proteins were evaluated in its place. The substitute
proteins were ranked on the improvement in the Wald test score, and KLK3.SerpinA3 was
close to as effective as C9.
The Kaplan Meier survival curves are shown in Figures 3A-4F for this ten
marker model of cardiovascular risk (Table 3).
Example 4. Univariate Analysis of the Relationship of Individual Proteins to the ic
type of CV Event
Cardiovascular events largely fall into two classes: otic and CHF.
Distinguishing between thrombotic and CHF risk has medical utility in guiding therapy,
choosing between anti-thrombotic and diuretic medications, for e. Although much of
the y is shared between the thrombotic and CHF classes of events, thrombotic events
specifically e the biology of blood coagulation (as implied by the name thrombotic).
Using the ten proteins of Table 3 identified in the Cox proportional hazard model (Example 3),
it was le to look for the signals linked to coagulation and to signals linked to tissue
remodeling. To determine any differential signal between the CHF and thrombotic events the
relevant Kaplan Meier curves were d separately for CHF and thrombotic events.
Platelets, or thrombocytes are a key player in the biology of coagulation. GPVI
is a platelet membrane glycoprotein, and for this protein, analysis was ted of the
association with event free survival for both CHF and thrombotic events in Figure 8 . Figure 8A
shows a strong association of thrombotic event free survival with the level of GPVI, plotted as
quartiles of the population distribution. Figure 8B shows that the les of GPVI are not
associated with event free survival for CHF events.
In contrast to GPVI, MATN2 (matrilin 2) is an extracellular matrix ated
protein. Figure 9A shows that the quartiles of MATN2 are not associated with risk for
otic events, while Figure 9B shows a strong association between MATN2 and CHF
events. The event free survival for those individuals with a MATN2 in the 4th quartile of the
population is markedly worse than the first three quartiles.
Taken together, the results of this example demonstrate that our ten protein
markers can discriminate between thrombotic events and CHF events in terms of the risk over a
few years after blood sampling.
Example 5. Usefulness of Angiopoietin 2 and CHRDL1 in Individuals Medicated
with s.
Many individuals are medicated with statins, both with known
cardiovascular disease, and many without specific cardiovascular conditions, such as those
with high LDL cholesterol. These powerful drugs alter the y of many biomarkers to
discriminate those at risk from those not at risk. It is valuable for biomarkers to function in
this population.
Figure 10 shows that in those subjects on statins, angiopoietin 2 is still
strongly useful for prediction of a CV event in high risk individuals. Figure10 shows
Kaplan Meier plots of all 538 subjects taking statin medication and illustrates that those
individuals in the 4th quartile of the population distribution for angiopoietin-2, suffer
cardiovascular events at an sed rate compared to those not in the 4th Quartile for
angiopoietin-2. Thus despite the effects of treatment with statins, oietin-2 is a
useful biomarker of the risk of cardiovascular events.
Figure 11 shows that in those subjects on statins, CHRDL1 is also
associated with the risk of cardiovascular events in this high risk population. Figure 11
shows Kaplan Meier plots of all 538 ts taking statin medication. It illustrates that
CHRDL1 is associated with the event free survival of vascular events in individuals
treated with statin medications. Thus, despite the effects of ent with statins,
CHRDL1 is a useful biomarker of the risk of cardiovascular events.
The reference in this specification to any prior publication (or information
derived from it), or to any matter which is known, is not, and should not be taken as an
acknowledgment or admission or any form of suggestion that that prior publication (or
ation derived from it) or known matter forms part of the common general
knowledge in the field of endeavour to which this specification s.
Throughout this specification and the claims which follow, unless the
context requires otherwise, the word "comprise", and variations such as ises" and
"comprising", will be tood to imply the inclusion of a stated integer or step or group
of integers or steps but not the exclusion of any other integer or step or group of integers or
steps.
Table 1: CV Event kers
r Gene Target Swiss Entrez PUBLIC_NAME Up or
Designation Name Prot Id Gene down
AKR1A1.4192. 1 AKR1A1 AK1A1 P14550 10327 Alcohol dehydrogenase up
0.2 (NADP+)/Ado-keto
reductase family 1 member
PGLYRP1.3329. PGLYRP PGRP-S 075594 8993 Peptidoglycan recognition up
14.2 1 protein, short
ROPvl .2590.69.4 ROR1 ROR1 Q01973 4919 Tyrosine-protein kinase up
transmembrane receptor
ROR1
ESAM.2981.9.3 ESAM ESAM Q96AP 90952 Endothelial cell-selective up
7 on molecule
VCAMl.2967.8. VCAM1 VCAM-1 P19320 7412 ar cell adhesion up
1 n 1/VCAM 1
CD5L.3293.2.3 CD5L CD5L 043866 922 CD5 antigen-like up
COL18A1 .2201 . COL18A Endostatin P39060 80781 Endostatin up
17.6 1
CTSZ.497 1.1 .1 CTSZ CATZ Q9UBR 1522 Cathepsin Z up
CCL18.3044.3.2 CCL18 PARC P55774 6362 Macrophage matory up
protein 4/Pulmonary and
activation-regulated
chemokine/CCLl 8
IGFBP4.2950.57 IGFBP4 IGFBP-4 P22692 3487 n-like growth up
.2 factor-binding protein 4
PLAUPv.2652.15. PLAUR suPAR Q03405 5329 Urokinase plasminogen up
1 activator e receptor
IL16.2774.10.3 IL16 IL-16 Q14005 3603 Interleukin-16 up
THBS2.3339.33. THBS2 TSP2 P35442 7058 Thrombospondin-2 up
IGFBP6.2686.67 IGFBP6 IGFBP-6 P24592 3489 Insulin-like growth up
.2 factor-binding protein 6
TNFRSF1A.265 TNFRSF TNF sR-I P19438 7132 Tumor necrosis factor up
4.19.1 1A or superfamily member
MATN2.3325.2. MATN2 MATN2 000339 4147 Matrilin-2 up
MMP1.4924.32. MMP1 MMP-1 P03956 4312 Matrix metalloproteinase up
1 1/collagenase 1
IGF1.2952.75.2 IGF1 IGF-I P05019 3479 Insulin-like growth factor I down
CRK.4976.57.1 CRK CRK P46108 1398 Adaptor protein Crk-I up
MB.3042.7.2 MB Myoglobin P02144 4151 Myoglobin up
SLPI.4413.3.2 SLPI SLPI P03973 6590 Secretory leukocyte protease up
inhibitor
IL18BP.3073.51 . IL18BP IL-18 BPa 095998 10068 Interleukin-18 binding up
2 protein
IL1RL1.4234.8.2 IL1RL1 IL-1 R4 Q01638 9173 Interleukin-1 receptor 4 up
F3.4931.59.1 F3 T P13726 2152 Tissue Factor up
930.21 .1 STC1 Stanniocalcin-1 P52823 6781 Stanniocalcin-1 up
ADIPOQ.3554.2 ADIPOQ Adiponectin Q15848 9370 Adiponectin up
PROC.2961 .1.2 PROC Protein C P04070 5624 Protein C down
REN.3396.54.2 REN Renin P00797 5972 Renin up
SOMAmer Gene Target Swiss Entrez PUBLIC_NAME Up or
Designation Name Prot Id Gene down
2913.1.2 CCL23 MPIF-1 P55773 6368 Myeloid progenitor inhibitory up
factor 3
LBP.3074.6.2 LBP LBP P18428 3929 Lipopolysaccharide-binding up
protein
GCG.489 1.50.1 GCG Glucagon P01275 2641 Glucagon up
YWHAG.4179.5 YWHAG 143 protein P61981 7532 143 protein g up
7.3 gamma
CCDC80.3234.2 CCDC80 URB Q76M9 15188 Coiled-coil up
3.2 6 7 domain-containing protein 80
CNTFR.271 1.6.2 CNTFR CNTFR alpha P26992 1271 Ciliary rophic factor up
receptor a
EFNA5.2615.60. EFNA5 Ephrin-A5 P52803 1946 Ephrin-A5 up
CST3.2609.59.2 CST3 Cystatin C P01034 1471 Cystatin C up
FUT5.4549.78.2 FUT5 FUT5 Q 11128 2527 Fucosyltransferase 5 up
TNFRSF17.2665 TNFRSF BCMA Q02223 608 B-cell tion protein up
.26.2 17
ERP29.4983.6.1 ERP29 ERP29 P30040 10961 Endoplasmic reticulum up
resident protein 29
RARRES2.3079. RARRES TIG2 Q99969 5919 Chemerin up
62.2 2
.3628.3 MAP2K2 MP2K2 P36507 5605 MAPK kinase 2 up
EPHA1. 343 1.54. EPHA1 EphAl P21709 2041 Ephrin type-A receptor 1 up
CLEC1 1A.4500. CLEC1 1 SCGF-alpha Q9Y240 6320 Stem Cell Growth Factor-a up
50.2 A
F10.4878.34.1 F10 Coagulation P00742 2159 Coagulation Factor X down
Factor X
CHITl. 3600.2.3 CHITl Chitotriosidase Q13231 1118 Chitotriosidase- 1 up
ITGA1.ITGB1..3 ITGA1 Integrin albl P56199, 3672 Integrin a-I: b-l complex up
503.4.2 ITGB 1 P05556 3688
CKB.CKM..371 CKB CK-MB P12277 1152 ne kinase-MB down
4.49.2 CKM P06732 1158
CTSB.3061.61.2 CTSB sin B P07858 1508 Cathepsin B up
CD163.5028.59. CD163 sCD163 Q86VB 9332 Scavenger receptor up
1 7 cysteine-rich type 1 n
Ml 30 chain/Soluble CD 163
PTN.3045.72.2 PTN PTN P21246 5764 Pleiotrophin up
CSFIR.2638.12. CSF1R M-CSF R P07333 1436 Macrophage up
2 colony-stimulating factor 1
receptor
IGFBP3.2571 .12 IGFBP3 IGFBP-3 P17936 3486 Insulin-like growth down
.3 -binding protein 3
CXCL12.3516.6 CXCL12 SDF-lb P48061 6387 Stromal cell-derived factor 1b up
PEBP1.4276. 10. PEBP1 prostatic P30086 5037 atidylethanolamine-bi up
2 binding protein nding protein 1
CCL22.3508.78. CCL22 MDC 000626 6367 Macrophage-derived up
3 chemokine
CST2.4324.33.2 CST2 CYTT P09228 1470 Cystatin SA up
CCL23.3028.36. CCL23 Ck-b1 P55773 6368 Ck-Pl/Macrophage up
2 inflammatory protein 3 splice
mem rane prote n
SOMAmer Gene Target Swiss Entrez PUBLIC_NAME Up or
Designation Name Prot Id Gene down
115 DCTPPl.4314.1 DCTPP1 XTP3A Q9H773 79077 dCTP pyrophosphatase 1 up
116 NID1 65.2 NIDI Nidogen P14543 481 1 Nidogen up
117 A2M.3708.62.1 A2M roglobu P01023 2 roglobulin up
118 FCGR3B.331 1.2 FCGR3B FCG3B 075015 2215 Immunoglobulin G Fc region up
7.1 receptor III-B, low affinity
119 PROC.3758.63.3 PROC Activated P04070 5624 Activated Protein C down
120 ADAMTS13.317 ADAMT ATS 13 Q76LX 11093 ADAM metallopeptidase down
.51.5 S13 8 with thrombospondin motifs
121 ANG.4874.3.1 ANG Angiogenin P03950 283 Angiogenin up
122 GRN.4992.49.1 GRN GRN P28799 2896 Progranulin up
123 CD48.3292.75.1 CD48 CD48 P09326 962 CD48 up
124 FGA.FGB.FGG. FGA D-dimer P02671 2243 D-dimer up
4907.56.1 FGB P02675 2244
FGG P02679 2266
125 IGHG1 .I IGHG1 IgG NA NA IgG
GHG3.IGHG4.I IGHG2
GK..IGL.. 3700. 1 IGHG3
.4 IGHG4
IGK@
IGL@
126 NAGK.3894. 15. NAGK NAGK Q9UJ70 55577 N-acetyl-D-glucosamine up
2 kinase
127 TNC.4155.3.2 TNC in P24821 3371 Tenascin up
128 RET.3220.40.2 RET RET P07949 5979 Proto-oncogene down
tyrosine -protein kinase
receptor Ret
129 MDK.291 1.27.2 MDK Midkine P21741 4192 Midkine up
130 TNFRSF10D.31 TNFRSF TRAIL R4 Q9UBN 8793 Tumor necrosis factor up
29.73.2 10D 6 receptor superfamily member
131 CD84.3642.4. 1 CD84 SLAF5 Q9UIB8 8832 Signaling lymphocytic up
activation molecule 5
132 EGFPv.2677. 1.1 EGFR ERBB1 P00533 1956 erbB 1/HERl down
133 SERPINA4.3449 SERPIN Kallistatin P29622 5267 Kallistatin down
.58.2 A4
134 MRC2.3041.55.2 MRC2 MRC2 Q9UBG 9902 Macrophage mannose up
0 receptor 2
135 GHR.2948.58.2 GHR Growth P10912 2690 Growth hormone receptor down
hormone
receptor
136 CXCL12.2330.2. CXCL12 SDF-la P48061 6387 Stromal cell-derived factor l up
137 SERPINF2.3024. F a2-Antiplasmin P08697 5345 a2-Antiplasmin down
18.2 2
138 RUNX2.3457.57 RUNX2 Osteoblast-spec Q13950 860 Osteoblast-specific up
.1 if transcr fact 2 transcription factor 2
139 CLEC1 6. CLEC1 1 SCGF-beta Q9Y240 6320 Stem Cell Growth Factor- b up
65.2 A
140 SIGLEC7.2742.6 SIGLEC7 Siglec-7 Q9Y286 27036 Siglec-7 up
2012/058060
SOMAmer Gene Target Swiss Entrez PUBLIC_NAME Up or
Designation Name Prot Id Gene down
141 VEGFA.2597 .8. VEGFA VEGF P15692 7422 Vascular endothelial growth up
3 factor A
142 BMPER.3654.27 BMPER BMPER Q8N8U 16866 Bone morphogenetic down
.1 9 7 protein—binding endothelial
regulator protein
143 SOD2.5008.51. 1 SOD2 Mn SOD P04179 6648 Superoxide dismutase [Mn] down
144 3634.5. OPCML OBCAM Q14982 4978 Opioid—binding cell adhesion down
4 molecule
145 181.50.2 CTSS Cathepsin S P25774 1520 Cathepsin S up
146 PLG.4151.6.2 PLG Plasminogen P00747 5340 Plasminogen down
147 PAFAH1B2.264 PAFAH 1 PAFAH beta P68402 5049 Platelet—activating factor up
2.4.1 B2 subunit acetylhydrolase lB subunit
B/PAFAH [3 subunit
148 lGFlR.4232.19.2 lGFlR lGF—l sR P08069 3480 Insulin—like growth factor I up
149 AGT.3484.60.2 AGT ensinoge P01019 183 Angiotensinogen down
150 GDF11.2765.4.3 GDFl 1 GDF—l 1 095390 10220 Growth—differentiation factor down
151 MMP14.5002.76 MMP14 MMP—14 P50281 4323 Matrix metalloproteinase up
.1 14/Membrane type matrix
metalloproteinase 1
152 SELP.4154.57.2 SELP ctin P16109 6403 P—Selectin up
153 BGN.3284.75.1 BGN BGN P21810 633 Biglycan up
154 IL6ST.2620.4.2 IL6ST gp130, soluble P40189 3572 Interleukin—6 receptor subunit up
B/gp130
155 PSMA2.4280.47. PSMA2 PSA2 P25787 5683 Proteasome subunit 0L2 up
Table 2 : List of 46 kers
SOMAmer Gene Target Swiss Prot Entrez PUBLIC_NAME Up or
Designation Name ID Gene Id down
VCAMl.2967.8. VCAM1 VCAM-1 P19320 7412 ar cell adhesion up
1 protein 1/VCAM 1
TNFRSF1A.265 TNFRSF1 TNF sR-I P19438 7132 Tumor necrosis factor up
4.19.1 A receptor superfamily
member 1A
CCDC80.3234.2 CCDC80 URB Q76M96 151887 Coiled-coil up
3.2 domain-containing protein
IL18BP.3073.51 . IL18BP IL-18 BPa 095998 10068 Interleukin-18 binding up
2 protein
IL1R1 .2991 .9.2 IL1R1 IL-1 sRI P14778 3554 Interleukin- 1 receptor 1 up
CXCL12.2330.2. CXCL12 SDF-la P48061 6387 Stromal cell-derived factor up
1 l a
PLA2G2A.2692. PLA2G2 NPS-PLA2 P14555 5320 Phospholipase A2, Group up
74.2 A IIA
CAPG.4968.50.1 CAPG CAPG P40121 822 Macrophage-capping protein up
CNDPl.3604.6.4 CNDP1 CNDPl Q96KN2 84735 Carnosine dipeptidase 1 down
ESAM.2981.9.3 ESAM ESAM Q96AP7 90952 Endothelial cell-selective up
adhesion le
MATN2.3325.2. MATN2 MATN2 000339 4147 in-2 up
LYZ.4920.10.1 LYZ Lysozyme P61626 4069 Lysozyme up
PLG.4151.6.2 PLG Plasminogen P00747 5340 Plasminogen down
0.43.2 C9 C9 P02748 735 Complement C9 up
LCN2.2836.68.2 LCN2 lin 2 P80188 3934 Lipocalin 2 up
NID1 .3213.65.2 NIDI n P14543 481 1 Nidogen up
CHST15.4469.7 CHST15 ST4S6 Q7LFX5 51363 Carbohydrate up
8.2 sulfotransferase 15
ROR1.2590.69.4 ROR1 ROR1 Q01973 4919 Tyrosine-protein kinase up
transmembrane receptor
ROR1
Table 3 : List of 10 kers
Table 4 : Heart & Soul Study tion Event Time and Type
Claims (7)
1. A method for determining the likelihood that an individual has increased risk of a CV event, the method comprising: detecting, in a biological sample removed from an individual, biomarker values that each correspond to one of at least N biomarkers selected from Table 1, and determining the likelihood that the individual has increased risk for a CV event based on said biomarker values, wherein N = 2 – 155 and wherein one of the at least N biomarkers selected from Table 1 is CCL18.
2. The method of claim 1, wherein N = 3 - 155; N = 4 - 155; N = 5 - 155; N = 6 - 155; N = 7 - 155; N = 8 - 155; N = 9 -155 or N = 10 - 155.
3. The method of claim 1 or claim 2, wherein the biomarkers in addition to CCL18 are selected from the group consisting of MMP-12, ment C7, PSA:αantichymotrypsin complex, GDF-11, αantiplasmin, angiopoietin-2 and a ation thereof.
4. The method of any one of claims 1 to 3, wherein detecting the biomarker values comprises performing an in vitro assay.
5. The method of claim 4, wherein said in vitro assay comprises at least one capture reagent corresponding to each of said biomarkers, and wherein said at least one capture reagent is selected from the group ting of aptamers, antibodies, and a nucleic acid probe.
6. The method of any one of claims 1 to 5, wherein the biological sample is selected from the group consisting of whole blood, dried blood spots, , serum and urine.
7. The method according to any one of claims 1 to 6, wherein said dual is evaluated for risk of a CV event, based on said ker values and at least one item of additional biomedical information corresponding to said dual, wherein said at least one item of additional biomedical ation is ndently selected from the group consisting of (a) information corresponding to the presence of cardiovascular risk factors selected from the group consisting of prior myocardial infarction, angiographic evidence of greater than 50% H:\fmt\Interwoven\NRPortbl\DCC\FMT\8534715_1.docx-
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161541828P | 2011-09-30 | 2011-09-30 | |
US61/541,828 | 2011-09-30 | ||
PCT/US2012/058060 WO2013049674A1 (en) | 2011-09-30 | 2012-09-28 | Cardiovascular risk event prediction and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ622118A NZ622118A (en) | 2016-01-29 |
NZ622118B2 true NZ622118B2 (en) | 2016-05-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200166523A1 (en) | Cardiovascular Risk Event Prediction and Uses Thereof | |
US9945875B2 (en) | Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) biomarkers and uses thereof | |
CA2961340C (en) | Cardiovascular risk event prediction and uses thereof | |
AU2015249162B2 (en) | Cardiovascular risk event prediction and uses thereof | |
US20220349904A1 (en) | Cardiovascular Risk Event Prediction and Uses Thereof | |
NZ622118B2 (en) | Cardiovascular risk event prediction and uses thereof | |
EP4232825A2 (en) | Cardiovascular event risk prediction | |
WO2022266031A2 (en) | Renal insufficiency prediction and uses thereof |